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The South-American social spider Parawixia bistriata produces a venom containing 
complex organic compounds with intriguing biological activities. The crude venom 
leads to paralysis in termites and stimulates L-glutamate uptake and inhibits GABA 
uptake in rat brain synaptosomes. Glutamate is the major neurotransmitter at the 
insect neuromuscular junction and at the mammalian central nervous system, 
suggesting a modulation of the glutamatergic system by the venom. Parawixin1, 2, 
and 10 (Pwx1, 2 and 10) are HPLC fractions that demonstrate this bioactivity. Pwx1 
stimulates L-glutamate uptake through the main transporter in the brain, EAAT2, and 
is neuroprotective in in vivo glaucoma models. Pxw2 inhibits GABA and glycine uptake 
in synaptosomes and inhibits seizures and neurodegeneration, and Pwx10 increases 
L-glutamate uptake in synaptosomes and is neuroprotective and anticonvulsant, 
shown in in vivo epilepsy models. Herein, we investigated the low molecular mass 
compounds in this venom and have found over 20 small compounds and 36 unique 
acylpolyamines with and without amino acid linkers. The active substances in fractions 
Pwx1 and Pwx2 require further investigation. We elucidated and confirmed the 
structure of the active acylpolyamine in Pwx10. Both, fraction Pwx10 and the 
synthesized component enhance the activity of transporters EAAT1 and EAAT2, and 
importantly, offer in vitro neuroprotection against excitotoxicity in primary cultures. This 
data suggests that compounds with this mechanism could be developed into therapies 
for disorders in which L-glutamate excitotoxicity is involved.          
Keywords: acylpolyamine, Parawixin10 (Pwx10), UHPLC, high-resolution MS, MS/MS, 
neurotransmitter, GABA, EAAT1, EAAT2, neuroprotection. 
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The spider Parawixia bistriata (Araneae; Araneidae) is a colonial orb-weaver 
species, found in the Southeast of Brazil, the North of Argentina, and Paraguay. The 
bioactivity of the P. bistriata venom was intensively studied by the group of Ferreira 
dos Santos. In 2000, it was shown that the venom, injected into termites, leads to 
irreversible and dose-dependent paralysis1. As L-glutamate serves as the major 
neurotransmitter at the insect neuromuscular junction2-3, these results indicated that 
the venom might mediate its action through the effects on the glutamatergic system. 
Additional in vitro studies showed that the crude venom stimulates L-glutamate uptake 
and inhibits γ-amino butyric acid (GABA) uptake in rat brain cortical synaptosomes in 
a concentration-dependent manner4, suggesting that the effects of the venom might 
also involve modulation of the GABAergic system.
Compounds which increase L-glutamate uptake are of interest as the over-
stimulation of glutamatergic postsynaptic receptors due to sustained elevation of 
extracellular L-glutamate levels in the synaptic cleft leads to excitotoxicity, which 
results in neuronal death through apoptosis/necrosis5-6. Glutamate excitotoxicity plays 
a key role in secondary damage following acute pathologies, including traumatic brain 
injury (TBI)7-14, hyper-excitability and seizures15-16, stroke17-21, epilepsy6, 16, 22-23, and 
cerebral and retinal ischemia8-9, 24-29. Excitotoxicity also produces secondary damage 
in chronic pathologies, including Amyotrophic lateral sclerosis (ALS)30-31, Alzheimer’s 
disease32, Huntington’s disease33-34, neuropathic pain35 and HIV-associated 
neurocognitive disorders (HAND)36-39. 
There are five structurally distinct subtypes of Na+-dependent EAAT transporters, 
including (rat/human homolog): GLAST/EAAT1/, GLT-1/EAAT2, EAAC1/EAAT3, 
EAAT4 and EAAT5, which allows for precise spatial and temporal regulation of L-
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glutamate neurotransmission40. Transporters EAAT1 and EAAT2, expressed 
predominantly in glia cells of the central nervous system, are the major transporters 
which take up synaptic glutamate to maintain optimal extracellular glutamic levels, 
thus preventing accumulation in the synaptic cleft and ensuing excitotoxicity 21, 41-44. 
Although expressed within the same astrocytic plasma membrane45, EAAT1 and 
EAAT2 display functional differences, for example, cell-surface protein expression of 
EAAT1 is affected by exogenous glutamate levels, but not EAAT2; and EAAT2 is 
regulated by neuronal soluble factors, unlike EAAT146-47. EAAT1 is highly expressed 
in the glial cells of the cerebellar Purkinje cell layer 48-49 and generally is expressed at 
higher levels in astrocytes and oligodendrocytes compared to microglia50. EAAT2 is 
primarily expressed in astrocytes and select neurons and oligodendrocytes of the 
brain and spinal cord44, 51, and accounts for approximately 95% of the total L-glutamate 
transport activity and 1% of total brain protein in the Central Nervous System (CNS)27, 
45, 52-54. Growing evidence shows that dysregulation of these transporters plays a 
significant role in excitotoxicity and associated neuropathogenesis. The expression 
and function of these astrocytic transporters may be dysregulated at the genetic, 
epigenetic, transcriptional or translational levels, leading to high levels of extracellular 
glutamate and excitotoxicity39, 55-59. On the other hand, the neuronal EAAT3 is 
ubiquitously expressed in the brain, it is important in maintaining low local 
concentrations of glutamate, where its predominant post-synaptic localization can 
buffer nearby glutamate receptors and modulate excitatory neurotransmission and 
synaptic plasticity60. Several diseases implicate in dysfunction of EAAT3, such as 
epilepsy, Obsessive-Compulsion disorder and schizophrenia 60. The neuronal EAAT4 
and glial EAAT1 are the two predominant EAATs responsible for maintaining low 
extracellular glutamate levels and preventing neurotoxicity in the cerebellum, the brain 
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region essential for motor control, by limiting mGluR1 signalling61. EAAT5 is important 
for control of glutamate release mediates light responses in depolarizing bipolar cells 
in retina62.
Termination of GABA-mediated neurotransmission is achieved by high-affinity 
transporters, named GATs, located at both GABAergic neurons and the surrounding 
astrocytes. GABA transporter subtype 1 (GAT-1, mainly presynaptic) and GABA 
transporter subtype 3 (GAT-3, mainly astrocytic) are the main transporters that 
regulate inhibitory GABAergic transmission in the mammalian brain through GABA 
reuptake63. The role of the neurotransmitter GABA in seizure disorders is not fully 
understood, but several studies indicate that the inhibition of GABA uptake could lead 
to suppression of seizures64-66. This is validated by studies using GABA analogues 
that were shown to exhibit pronounced anticonvulsant activity in a variety of animal 
seizure models, including tiagabine, a GAT inhibitor that has been developed as a 
clinically active antiepileptic drug67. Moreover, glycine transporters-1 and -2 (GlyT1, 
and GlyT2), regulate extracellular glycine concentrations within the CNS and as such, 
play critical roles in maintaining a balance between inhibitory and excitatory 
neurotransmission. The GlyT1 subtype is expressed by astrocytes at both inhibitory 
and excitatory synapses as well as by a subset of glutamatergic neurons, whereas the 
expression of GlyT2 is predominantly restricted to presynaptic terminals of inhibitory 
glycinergic neurons68. GlyT-1 inhibition has been extensively examined as a potential 
means to treat several CNS disorders that include schizophrenia, depression, anxiety, 
addiction, pain, Parkinson's disease, and epilepsy69. Modulation of GlyT2 transporters 
could provide therapeutic avenues for chronic pain, as exemplified by N-arachidonyl-
glycine (NAGly), an endogenous lipid that inhibits glycine transport by GlyT2 and 
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shows potential as an analgesic68, and novel allosteric modulators of GlyT2 with 
translational potential for pain analgesia70. 
The neuroactive properties of the venom of P. bistriata appeared to be related to 
three HPLC fractions previously isolated from the spider venom, namely Parawixin1 
(Pwx1)4, 71, Parawixin2 (Pwx2)72-77, and Parawixin10 (Pwx10)78-79, containing strongly 
polar, low molecular mass compounds.
The most polar fraction, called Pwx1, was shown to increase the rate of L-
glutamate uptake in vitro selectively through L-glutamate transporter EAAT2. 
Importantly, the Pwx1 fraction also had neuroprotective properties in an in vivo model 
of glaucoma71. Additionally, the structural region of the transporter in which Pwx1 
interacts sits at the interface of the rigid trimerization domain and of the central 
substrate-binding transport domain, allowing for the identification of an allosteric site 
that is important for transport stimulation80. Further studies used an in silico approach 
to screen for novel compounds that interact with this allosteric site and were shown to 
be positive allosteric modulators of EAAT281. Importantly, additional studies revealed 
that this class of compounds had also in vitro neuroprotective properties82, validating 
the premise that increasing L-glutamate clearance by activation of EAAT2 transport 
could serve as means of achieving neuroprotection82. 
The fraction Pwx2 inhibited the uptake of GABA and glycine in synaptosomes 
and exhibited anticonvulsant effects in chemically-induced seizures models in a dose-
dependent manner73-74, 77. Furthermore, this fraction exhibited anxiolytic, 
neuroprotective and anti-epileptic effects in in vivo models of Temporal Lobe 
Epilepsy72, 76. The chemical structure of the active component in the fraction Pwx2, 
also called FrPbAII, was proposed as 2-amino-5-ureidopentanamide73.
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Fraction Pwx10 was shown to increase L-glutamate uptake in rat brain 
synaptosomes78 and to have neuroprotective and anticonvulsant activities in in vivo 
epilepsy models of intrahippocampal N-methyl-D-aspartate microinjection, and 
pentylenetetrazole injection in the lateral ventricle79. 
With all these promising biological activities found, we decided to investigate the 
chemical structures of the low molecular mass components of the P. bistriata venom 
by UHPLC-HR-ESI-MS and MS/MS in an untargeted approach to get a better 
understanding of the complex venom composition. We were especially interested in 
the structure elucidation and the synthesis of the compounds that caused the observed 
activities in the Pwx1, Pwx2, and Pwx10 fractions in order to confirm structure and 
biological activity. 
In this work, we have elucidated the structure of 36 acylpolyamines, with and 
without amino acid linkers, in the venom of the P. bistriata spider. One of them is the 
structure of (S)-N1-(3-(2-amino-5-guanidinopentanamido)propyl)-N4-(3-(2-(4-
hydroxy-1H-indol-3-yl)acetamido)propyl)-N1,N1,N4,N4-tetramethylbutane-1,4-
diaminium iodide (4-OH-IndAc3(Me2)4(Me2)3Arg2+), that had equivalent biological 
activity to Pwx10. This compound was revealed to be a doubly charged acylpolyamine 
derivative showing a non-selective allosteric modulation of astrocytic L-glutamate 
transporters. Importantly, this compound was neuroprotective in in vitro models of 
excitotoxicity, suggesting that this class of compounds could be further developed into 
therapies for neurological disorders that involved L-glutamate excitotoxicity.
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Structure elucidation of the low molecular mass compounds in P. 
bistriata venom
The P. bistriata venom was extracted from the spider glands with H2O/MeCN 
9:1 (v/v) and then analyzed by UHPLC-HR-ESI-MS and MS/MS. The venom was 
chromatographed on a RP C18+ core shell column and a mobile phase composed of 
H2O/MeCN + 0.1% TFA, conditions particularly suited for the separation of polar basic 
compounds. The MS/MS spectra were recorded in an untargeted approach with the 
selection of maximum five different precursor ions after one survey scan. In addition, 
the number of exchangeable protons of the spider venom metabolites was determined 
in an on-line H/D exchange experiment.
The low molecular mass compounds (< 1000 Da) in spider venom can be 
classified into acylpolyamine derivatives and other small molecules. The structure of 
these polyamine derivatives was elucidated based on the MS/MS fragmentation rules 
defined by Tzouros et al.83. These rules allow the unambiguous identification of 
acylpolyamines from their MS/MS fragment ions without the need of synthesized 
reference material. All polyamine derivatives were named according to the generic 
acylpolyamine nomenclature84. More details about acylpolyamine nomenclature can 
also be found in the supplementary material (including Figure 1 and tables 1-3). The 
structures of the other small compounds, which are not polyamine derivatives and, 
thus, do not follow the fragmentation rules of acylpolyamines, were confirmed by the 
analysis of reference material.
The base peak chromatogram (BPC) of a sample of crude P. bistriata venom 
measured by UHPLC-HR-MS is shown in Figure 1. With the untargeted approach, the 
MS and MS/MS spectra of more than 75 features were recorded. Of these, 58 
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structures could be resolved. The signals related to the proposed biologically active 
candidates found in the peak corresponding to the Pwx2 (P+ = m/z 175.12)73 and 
Pwx10 (m/z 294.72)78 fractions were detected with a retention time of 1.13 min and 
6.84 min, respectively. The molecular mass (437 Da)4 characterizing the main 
compound described in the Pwx1 fraction, however, could not be related to any signal 
observed from the crude spider venom. Since there is no other structure-related 
information about the active substance in Pwx1 fraction4 and the originally isolated 
fraction was no longer accessible, the structure of the active substance in Pwx1 
fraction was not further investigated in this study.
Structure elucidation of the active compound in the Pwx2 fraction
Previous studies proposed 2-amino-5-ureidopentanamide (FrPbAII) as the 
active structure in the Pwx2 fraction73. In our studies, the structure of the active 
compound in the Pwx2 fraction was re-examined. 
In the UHPLC-MS chromatogram of the crude P. bistriata venom, the peak 
related to m/z 175.11909 ([M+H]+) was detected with a retention time of 1.13 min. 
Although retention time and accurate masses were in good agreement with 
commercially available FrPbAll (1.15 min and C6H15N4O2, ∆m/z = 0.78 ppm), the 
MS/MS spectra are clearly proving the presence of arginine (∆m/z = 3.63 ppm), a 
structural isomer of FrPbAll (Figure 2). Our bioactivity tests with commercially available 
FrPbAII did not show any effect on the inhibition of GABA (Figure 3B). Additionally, 
the activity assays of arginine (Figure 3C) did not match to what was observed for the 
isolated fraction Pwx2, as none of the concentrations of arginine tested elicited 
inhibition of GABA uptake. This suggests that another co-eluting small molecule from 
the spider venom may trigger the action of Pwx2. 
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In total, 22 small compounds (mainly nucleosides, amino acids and quaternary 
amines) were identified within the venom of P. bistriata (see supplementary material 
for comprehensive data including all MS/MS spectra obtained from the spider venom 
as well as the corresponding reference compounds) whereby only one of the identified 
small compounds, namely inosine, was previously found in the P. bistriata venom85. 
Inosine induced convulsive seizures in rats after intracerebroventricular injection, 
whereas an analogue, inosine 5'-monophosphate, induced a delayed paralysis in 
termites85. In addition, adenosine and guanosine as well as the related free bases, 
adenine and guanine, were detected86-89. Nucleosides have already been found in the 
venom of several spider families90-91. 
In addition to arginine, which has been found in the fraction of Pwx2, the amino 
acids leucine, isoleucine, glutamic acid, glutamine, phenylalanine, tyrosine, and 
tryptophan were detected. Of all these compounds, only glutamic acid has been 
reported several times as component of spider venoms91. In insects, L-glutamate is 
an excitatory neurotransmitter at the neuromuscular junction2-3. The ion channel of the 
activated postsynaptic L-glutamate receptor can be inhibited by acylpolyamine 
compounds, which cause reversible paralysis of the spider's prey92-94. It seems to be 
quite reasonable that the L-glutamate and acylpolyamines together make the venom 
highly efficient. However, until now the combination of L-glutamate and 
acylpolyamines have only been found in venoms of spiders from the Araneidae 
family91, in which P. bistriata belongs. 
The venom further contains a number of quaternary amines, including choline, 
which was previously detected in various spider venoms88, betaine, carnitine, 
acetylcarnitine, propionyl carnitine, and homarine found for the first time in the spider 
venom. The presence of homarine uniquely stands out since it is a compound that to 
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the best of our knowledge is only known from marine species. Lastly pantothenic acid 
as well as the polyamines spermine and spermidine were found. However, none of 
the three β-carboline toxins, PwTx-I95, PwTx-II96 and 1-guanidino-6-hydroxy-3,5-
dihydro-β-carboline97 described by the group of Palma, nor structural related 
compounds, were detected. 
Activity of constituents of the fraction Pwx2
We have examined and compared the effects of the natural Pwx2 fraction with 
the commercially available FrPbAII on both GAT-1 and GAT-3 mediated GABA 
transport, as well as GlyT1 and GlyT2 mediated glycine transport. Experiments were 
performed in COS-7 transiently transfected with the appropriate DNA and empty 
vector for background. Two days after transfection, a dose response assay of Pwx2 
was conducted, in presence of 50 nM of the appropriated radiolabelled isotope (figure 
3). The Pwx2 fraction inhibited GABA uptake mediated by GAT-1 with an IC50 of 117 
± 6 µM, while it had no effect on GABA uptake mediated by GAT-3, and glycine uptake 
mediated by GlyT1 and GlyT2 (Figure 3A). In a previous study, natural Pwx2 fraction 
was shown to inhibit GABA uptake in cortical synaptosomes with an IC50 of 24 μg/ml, 
which is equivalent to 114 µM73, a comparable value for the inhibition of GAT-1 
observed herein. We also examined Pwx2 concentrations higher than 500 mM, and 
they did not inhibit GAT-1 mediated uptake more than ~52% (not shown in the graph 
for simplicity). Suggesting that the natural Pwx2 fraction, even though seemingly 
selective for GAT-1 rather than GAT-3 and glycine transporters, is a weak and poorly 
efficacious GAT-1 inhibitor, compared to other specific inhibitors, such as SKF 89976A 
hydrochloride (IC50 of 0.13 μM for GAT-1 inhibition98) and tiagabine, an anticonvulsant 
with an IC50 of 67 nM in vivo67, 99. Also, we did not observe any effect of the fraction 
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Pwx2 on glycine uptake mediated by GlyT1 or GlyT2 (figure 3), even though in the 
previous work it was reported to inhibit glycine uptake in synaptosomes and retinal 
preparations73. Further experiments to examine whether Pwx2 modulates other 
transporters, or has indirect effects on other targets, are needed to understand this 
discrepancy. 
The commercial compound FrPbAII did not affect either GAT-1, GAT-3, GlyT1 
or GlyT2 mediated GABA or glycine transport, as shown in Figure 3B, confirming that 
the active constituent of the Pwx2 fraction is not the originally proposed FrPbAII. The 
revised structure containing arginine was also tested against these 4 subtypes of 
transporters. However, a dose response of arginine shows that there is no effect on 
GAT-1, GAT-3, GlyT1 and GlyT2, suggesting that the active compound in the fraction 
Pwx2 is not arginine either (figure 3C). Since arginine, the main compound of the Pwx2 
fraction, is not active, we speculate that the inhibiting effect of the isolated fraction 
Pwx2 on GAT-1 activity is either due to a minor compound or to unknown synergistic 
effects among different molecules within the venom. Figure 3D shows the background 
of GABA uptake assays obtained in presence of 1 mM nipecotic acid, resulting in 
inhibition of 98 ± 1.5% by GAT-1, 75 ± 4% by GAT-3. Specific GlyT1 inhibitor sarcosine 
results in inhibition of 90 ± 8% and specific GlyT2 inhibitor N-arachidonylglycine results 
in inhibition of 95 ± 3 %, meaning that our uptake approach was fully functional. 
Other potential candidates that could be causing the effect of the Pwx2 fraction 
were explored, in addition to several small compounds which have been detected in 
the crude P. bistriata venom (supplementary figure 2), on GABA uptake mediated by 
GAT-1 and GAT-3 transporters, and glycine uptake mediated by GlyT1 transporter. 
Betaine, homarine, L-carnitine hydrochloride, spermidine trihydrochloride and 
spermine were examined, as they similar short retention times in the chromatographic 
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separation when the crude venom was analyzed and therefore might be part of the 
originally isolated fraction Pwx2. Homarine, carnitine and betaine, however, did not 
affect the activities of the transporters examined (supplementary figure 2A-C). On the 
other hand, spermidine and spermine selectivity increased the activity of GAT-1 
mediated GABA uptake, without affecting the activities of GAT-3 or GlyT1 
(supplementary figures 2D and E show the effects of spermidine trihydrochloride and 
spermine on GAT-1, respectively, with variable EC50s and efficacies). Therefore, 
spermidine and spermine increase GAT-1 activity, an effect that seems counter-
intuitive, as increased GABA transport results in less inhibitory neurotransmitter at the 
neuromuscular junction of insects, resulting in more excitatory inputs. However, we 
speculate that these effects would be annulled by the inhibiting effect of the Pwx2 
fraction in GABA transport, resulting in paralysis of insects, as previously shown1. 
These findings suggest that the active constituent in the fraction Pwx2 is neither of 
these compounds. 
Selective modulation of the GABA uptake process through pharmacological 
agents has been explored over several decades. These studies have demonstrated 
that inhibition of astroglial, but not neuronal, GATs may be preferred for anticonvulsant 
action. Only recently a class of specific GAT-3 inhibitors, which act by allosteric 
modulation, were elucidated100. However, it remains to be investigated whether this 
class of compounds has efficacy for conditions such as epilepsy in preclinical studies. 
So far, the only compound with notable inhibitory effects at GATs, tiagabine, has 
demonstrated clinical anticonvulsant efficacy, and is, to date, the only approved GAT 
inhibitor for clinical use. Thus, efforts to identify and develop GAT subtype-specific 
compounds continue to be an area of active investigation for the management of 
epilepsy and other CNS disorders101.
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Structure elucidation of the acylpolyamine derivatives
Earlier studies suggested that the neuroprotective effect of the fraction Pwx10 
is probably due to an acylpolyamine associated with the doubly charged ion m/z 
294.778. The corresponding peak in the UHPLC-MS chromatogram of the P. bistriata 
crude venom was found at 6.84 min (Figure 1). Figure 4 displays the full scan (FS)-
HR-MS spectrum related to the chromatographic peak. The molecular formula derived 
from the doubly charged ion m/z 294.72047 is C30H55N9O32+ (–1.00 ppm). The 
associated singly charged ion (m/z 588.4) was not detected. Instead, signals of TFA 
adducts at m/z 702.42615 ([M2++TFA-]+, C32H55N9O5F3+, –1.60 ppm), m/z 351.71694 
([M2++TFA-+H+]2+, C32H56N9O5F32+, –0.98 ppm) and m/z 816.41902 ([M2++2TFA-+H+]+, 
C34H56N9O7F6+, –1.37 ppm) and even the signal of the triply charged ion at 
m/z 196.81624 ([M2++H+]3+ C30H56N9O33+, –0.42 ppm) were detected.
The structure of the acylpolyamine related to the main component of the Pwx10 
fraction was elucidated by the MS/MS spectrum obtained from the precursor m/z 
816.42 which was the only precursor that resulted in signals above m/z 231 (see 
supplementary material). The compound was identified as 4-OH-
IndAc3(Me2)4(Me2)3Arg2+ (compound 12; Figure 5). The base peak ion of the MS/MS 
spectrum m/z 231.11269 (a1, C13H15N2O2+, –0.49 ppm) together with the ion m/z 
146.06007 (a’, C9H8NO+, –0.20 ppm) indicated that the acylpolyamine has a 4-
hydroxy-indol acetyl head moiety connected to a C3 amine unit. Further, the spectrum 
showed the fragments m/z 214.16636 (z1, C9H20N5O+, 0.58 ppm), m/z 197.13970 (y1, 
C9H17N4O+, 0.06 ppm), m/z 157.10854 (C6H13N4O+, 0.97 ppm), m/z 155.11782 (z1-
Gu, C8H15N2O+, –0.45 ppm) and m/z 139.09792 (C6H11N4+, 0.70 ppm), distinctive for 
an arginine tail linked to a C3 unit. The identified head and tail units had to be linked 
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by a fragment related to the formula C8H20N2. The large number of hydrogen atoms 
indicated that the head and tail were not simply connected by a linear C8-unit. In fact, 
only a C4-unit framed by two dimethylated nitrogen atoms matched the molecular 
formula of the acylpolyamine. This structure was in good agreement with the remaining 
major signals at m/z 100.11254 (dimethyl-pyrrolidin [C6H14N]+, 4.64 ppm), m/z 
259.22392 (tz1, C11H27N6O+, –0.64 ppm), m/z 313.27065 (z2, C15H33N6O+, -1.23 ppm) 
and m/z 330.21728 (a2, C19H28N3O2+, –0.98 ppm).
The presence of tetrasubstituted N-atoms in the acylpolyamine structure was 
confirmed in an H/D exchange experiment. The shift from m/z 294.72047 ([M]2+, 
C30H55N9O32+, –1.00 ppm) to m/z 299.75276 ([d10-M]2+, C30H45D10N9O32+, 1.77 ppm) 
confirmed the presence of 10 exchangeable hydrogen atoms. This finding supports 
the proposed structure 4-OH-IndAc3(Me2)4(Me2)3Arg2+.
The structure of 4-OH-IndAc3(Me2)4(Me2)3Arg2+ (12) was confirmed by the 
synthesis of reference material (compound 12, see below). This acylpolyamine 
derivative has never been described before. However, acylpolyamines with quaternary 
amines in the polyamine backbone were previously reported by Grishin et al.102 in 
Argiope lobata, Araneidae and by Yamaji et al.103 in Macrothele gigas, Hexathelidae.
Besides the acylpolyamine related to the Pwx10 fraction, the structures of 35 
additional acylpolyamines were elucidated from the venom of the spider P. bistriata. 
All elucidated structures are summarized in the matrix shown in Figure 6 and their 
respective backbone, tail, and head highlighted as green squares. The rows represent 
the head moiety and the columns a polyamine backbone of the corresponding 
structure (refer to supplementary material for the drawn structures and the MS/MS 
spectra of all the identified polyamine compounds). To our knowledge, only two of the 
identified acylpolyamines have been described so far. The structure of N-(5-
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aminopentyl)-2,5-dihydroxy-benzamide (2,5-(OH)2-Bz5) was reported in the venom of 
a Drassodes species (Gnaphosidae)104. N1-5-aminopentyl)-2-[(1H-indol-3-
ylacetyl)amino]-butanediamide (IndAcAsn5, Pseudoargiopinin3) was earlier found in 
the spider venom of Argiope lobata102, a species that belongs, as P. bistriata, to the 
family of Araneidae.
Surprisingly, the venom of P. bistriata contained both types of acylpolyamines 
with and without amino acid linkers. They are both well known, but to the best of our 
knowledge they were never found coexisting in a spider venom until now. P. bistriata 
spider belongs to a more recent evolved group which also has characteristics of 
ancestral groups91. We speculate the presence of both acylpolyamines types could be 
related to the evolution process of this group; however, detailed studies on spider 
venom content attempting to correlate the phylogenetic relationships between various 
species of the Araneidae family are needed. 
Acylpolyamines with the three amino acids asparagine (Asn), lysine (Lys), and 
arginine (Arg) in their backbone were already described by Grishin et al. (A. lobata, 
Araneidae)102 and Wakamiya et al. (Nephila species, Nephilidae)105-106. They were 
isolated and their structures elucidated by NMR.
Somehow unusual seems the presence of the acylpolyamines N1-(4-(2-amino-
5-(dimethylamino)pentanamido)butyl)-2-(2-(2,4-
dihydroxyphenyl)acetamido)succinamide (2,4-(OH)2-PhAcAsn4Orn(NMe2), see 
Supplementary Material p. 27), and 2-(2-(1H-indol-3-yl)acetamido)-N1-(4-
aminobutyl)pentanediamide (IndAcGln4, see Supplementary Material p. 20) as they 
are, so far, the only derivatives in the venom that possess an ornithine or a glutamine 
unit in their backbones. However, as for all other elucidated structures, the MS/MS 
and the determined number of exchangeable H-atoms support the proposed 
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structures. While glutamine was not found in a polyamine backbone before, ornithine 
was earlier found in nephilatoxins (Nephila clavata), where the presence of ornithine 
was confirmed by amino acid analysis107.
Finally, the two bis-acetylated polyamine derivatives N,N'-
(azanediylbis(propane-3,1-diyl))bis(2,5-dihydroxybenzamide) (2,5-(OH)2-Bz33-(2,5-
(OH)2-Bz)) see Supplementary Material p. 23) and N-(3-((4-(2,5-
dihydroxybenzamido)butyl)amino)propyl)-2,5-dihydroxybenzamide (2,5-(OH)2-Bz34-
(2,5-(OH)2-Bz)), mygalin, see Supplementary Material p. 25) were detected. Their 
experimental data are in good agreement with the reported ESI-MS/MS spectrum of 
mygalin that was isolated from the hemocytes of the spider Acanthoscurria gomesiana 
(Theraphosidae)108.
Synthesis of 4-OH-IndAc3(Me2)4(Me2)3Arg2+ (12)
The synthesis of 4-OH-IndAc3(Me2)4(Me2)3Arg2+ (12) was developed in order 
to unequivocally confirm the structure of the active compound in the Pwx10 fraction 
as compound 12 by comparison of structure and biological activity. The synthesis of 
the N-Boc protected, methoxy-indole intermediate, 10, is shown in Scheme 1. In 
reaction (1) N,N-dimethylpropane-1,3-diamine (1) was coupled to (S,Z)-5-(2,3-bis(tert-
butoxycarbonyl)guanidino)-2-((tert-butoxycarbonyl) amino) pentanoic acid (2) by the 
action of the coupling reagent T3P to provide the key N,N-dimethylpropane tri-N-Boc 
protected arginine amide (3), which will become the right hand side motif of 4-OH-
IndAc3(Me2)4(Me2)3Arg2+ (12). In reaction (2) 4-methoxy-1H-indole, 4, was reacted 
with oxalyl chloride followed by quenching with methanol to produce methyl 2-(4-
methoxy-1H-indol-3-yl)-2-oxoacetate, 5. The reactive carbonyl in 5 is reductively 
removed under palladium hydrogenation conditions to yield methyl 2-(4-methoxy-1H-
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indol-3-yl)acetate, 6, which is then hydrolysed to provide 2-(4-methoxy-1H-indol-3-
yl)acetic acid, 7. Compound 7 is then used to build the left-hand side motif of 4-OH-
IndAc3(Me2)4(Me2)3Arg2+ (12), first by amide coupling with diamine 1, by the action of 
T3P in Hunigs base and dichloromethane, followed by alkylation with 1,4-diiodobutane 
to provide 4-iodo-N-(3-(2-(4-methoxy-1H-indol-3-yl)acetamido)propyl)-N,N-
dimethylbutan-1-aminium iodide, 9. Alkylation of 9 by the N,N-dimethyl amine of 
intermediate 3 shown in reaction (4) provides the protected precursor, (S,Z)-N1-(6,11-
bis((tert-butoxycarbonyl)amino)-2,2-dimethyl-4,12-dioxo-3-oxa-5,7,13-triazahexadec-
5-en-16-yl)-N4-(3-(2-(4-methoxy-1H-indol-3-yl)acetamido)propyl)-N1,N1,N4,N4-
tetramethylbutane-1,4-diaminium iodide, 10. 
Scheme 2 shows the first approach at a stepwise removal of the protecting 
groups by first removing the N-Boc protecting groups in reaction (5) by the action of 
trifluoroacetic acid in dichloromethane to provide the methoxyindole 11. However, due 
to the polarity of 11, we were unsuccessful in being able to further remove the indole 
methoxy group for this compound. Therefore, as shown in reaction (6) 10 was treated 
with boron tribromide at -78 oC to remove the indole methoxy group under mild 
conditions. Then by allowing the reaction mixture to slowly warm to room temperature 
the reaction mixture became acidic enough to remove the N-Boc protection to provide 
4-OH-IndAc3(Me2)4(Me2)3Arg2+ (12), in a 45% yield after reverse phase HPLC 
purification. Please see supplementary material for NMR and MS spectra for all 
compounds.
Compound 12 was then fully characterized for comparison against the isolated 
compound from the spider venom, and further evaluated for biological activity in 
neurotransmitter transport and neuroprotection assays, as described below. 
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Effects of Pwx10 fraction, and compounds 11 and 12 on neurotransmitter 
transporter studies 
Our results indicate that the natural Pwx10 fraction stimulated L-glutamate 
uptake through EAAT1 and EAAT2 with no effects on EAAT3-mediated uptake. Figure 
7A shows dose response curves for the effect of the Pwx10 fraction, with the potencies 
and efficacies are expressed as mean ± SD of three independent experiments. The 
compound was found to have similar potencies for EAAT1 and EAAT2- mediated L-
glutamate uptake, with EC50 of 5.8 ± 2.9 nM for EAAT1 and 5.2 ± 2.4 nM for EAAT2. 
Efficacies of uptake augmentation were also similar, with 162 ± 11% for EAAT1 and 
168 ± 9 for EAAT2. To validate the effect of natural Pwx10 fraction in an endogenous 
system, we performed dose response assays for the Pwx10 fraction in cultured glia 
(Figure 7B), and demonstrated that the compound has a potency of 22 ± 7 nM and 
efficacy of 314 ± 16% for L-glutamate uptake augmentation. 
L-glutamate uptake kinetic analysis of the effect of different concentrations of 
the Pwx10 fraction (10, 100 and 500 nM) in EAAT1 and EAAT2 transfected cells, 
respectively, are shown in Figure 7C and D. For EAAT1-mediated uptake, Vmax values 
were significantly increased, from 127 ± 15 pmol/well/min for control (vehicle) 
conditions, to 168 ± 7, 313 ± 33 and 783 ± 23 pmol/well/min in presence of increasing 
concentrations of the Pwx10 fraction. Km values were not significantly different among 
conditions. For EAAT2-mediated uptake, Vmax values were significantly increased, 
from 133 ± 14 pmol/well/min for control (vehicle) conditions, to 170 ± 9, 309 ± 19 and 
797 ± 26 pmol/well/min in presence of increasing concentrations of the Pwx10 fraction. 
Km values were not significantly different among conditions. These results that the 
active compound in the Pwx10 fraction acts as a non-selective enhancer of the activity 
of both subtypes of astrocytic L-glutamate transporters EAAT1 and EAAT2. Since the 
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affinity for the substrate (Km) values were not significantly different among conditions 
(One-way ANOVA followed by Dunnett's post-hoc test comparing to vehicle), with an 
average ± SD of 53 ± 4 M for EAAT1 and 52 ± 6 M for EAAT2, we propose that the 
mechanism of stimulation to be through positive allosteric modulation of the 
transporters. Figure 7E shows a kinetic experiment performed in cultured glia in 
presence of different concentrations of the Pwx10 fraction, showing that the Vmax 
values were significantly increased, from 19.7 ± 1 pmol/well/min for control (vehicle) 
conditions, to 38.2 ± 1.3 and 59.4 ± 3.3 pmol/well/min in presence of 100 and 500 nM 
Pwx10 fraction. Similarly to the results in transfected cells, the Km values were not 
significantly different among conditions (One-way ANOVA followed by Dunnett's post-
hoc test comparing to vehicle), with an average ± SD of 44 ± 3 M, suggesting once 
again that the active compound in the Pwx10 fraction might be an allosteric modulator 
of the activity of the transporters. 
We proceed with our studies to examine the actions of synthesized compounds 
11 and 12 (shown in Scheme 2). Compound 12 corresponds to the structure of the 
potential active substance in the isolated Pwx10 fraction and compound 11 is a 
structural analogue that has a methoxy group on the left-hand side indole ring instead 
of a hydroxyl group. Dose response curves for the effects of 12 and 11 in transfected 
COS-7 cells are shown in Figure 8A and B, respectively. Acylpolyamine 12 increases 
EAAT1-mediated L-glutamate uptake with an EC50 of 0.4 ± 0.2 nM and efficacy of 171 
± 15%, and for EAAT2-mediated uptake with an EC50 of 0.8 ± 0.1 nM and potency of 
144 ± 7%, with no effect on EAAT3-mediated L-glutamate uptake. Figure 8C shows 
dose response assays for 12 and 11 in cultured glia, demonstrating that the 
compounds increase L-glutamate uptake in this approach, however, the potency of 12 
is higher (EC50 of 21 ± 0.6 nM) as compared to 11 (EC50 of 690 ± 50 nM), whereas 
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efficacies for augmentation were similar (178 ± 9% for 12 and 155 ± 9% for 11), 
indicating that the methoxy group in 11 results in lower potency for L-glutamate 
augmentation. 
Kinetic analysis of L-glutamate uptake in presence of different concentrations 
of 12 and 11 are shown in Figures 8D-F. For EAAT1-mediated uptake (figure 8D), Vmax 
values were significantly increased, from 185 ± 15 pmol/well/min for control (vehicle) 
conditions, to 303 ± 26 and 723 ± 44 pmol/well/min in presence of 100 and 500 nM of 
12, and to 241 ± 22 and 475 ± 27 pmol/well/min in presence of 100 and 500 nM of 11. 
For EAAT2-mediated uptake (Figure 8E), Vmax values were significantly increased, 
from 127 ± 12 pmol/well/min for control (vehicle) conditions, to 262 ± 22 and 613 ± 55 
in presence of 100 and 500 nM 12, and to 271 ± 19 and 586 ± 22 pmol/well/min in 
presence of 100 and 500 nM 11, respectively. Km values were not significantly different 
among conditions (One-way ANOVA followed by Dunnett's post-hoc test comparing 
to vehicle), with an average ± SD of 62 ± 22 M for EAAT1 and 57 ± 7 M for EAAT2. 
These results demonstrate that 12 and 11 act as a non-selective enhancer of the 
activity of both subtypes of astrocytic L-glutamate transporters EAAT1 and EAAT2, 
with potentially an allosteric mechanism, since the affinity for the substrate (Km) value 
was not different. Figure 8F shows kinetic experiments performed in cultured glia 
showing that the Vmax values were significantly increased, from 18.1 ± 1 pmol/well/min 
for control (vehicle) conditions, to 33 ± 2 and 55 ± 2 pmol/well/min in presence of 100 
and 500 nM 12 and 28 ±1 and 37 ±2 pmol/well/min in presence of 100 and 500 nM 
11. Similarly to the results in transfected cells, the Km values were not significantly 
different among conditions (One-way ANOVA followed by Dunnett's post-hoc test 
comparing to vehicle), suggesting once again that these compounds enhance the 
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glutamate translocation rate, with no effect on substrate interaction, suggesting an 
allosteric mechanism. 
Collectively, results in Figure 8 indicate that the bioactivity of synthetic compounds 
12 and 11 match the activity of the natural Pwx10 fraction, with 11 being slightly less 
potent in cultured glia cells. This data suggests that the 4-methoxy substituent on the 
indole ring of 11 does not negatively impact the biological activity of this component 
and inspires the synthesis of additional substituted indole analogs in the future to 
elaborate on the structure activity relationships for this motif. Notably other polyamine 
spider toxins containing a 4-hydroxy-indole acetic acid moiety, such as in 12, are found 
to be less toxic than those with a hydroxyphenyl-based aromatic head group109. With 
these results of the activity study and the confirmation that the structure of compound 
12 corresponds to the acylpolyamine in the P. bistriata venom, we conclude that the 
acylpolyamine 4-OH-IndAc3(Me2)4(Me2)3Arg2+ (12) is the active compound in the 
fraction Pwx10.
Neither the natural Pwx10 fraction nor the synthetic compounds 12 and 11 have 
any effect on GABA uptake mediated by GAT-1 and GAT-3, glycine uptake mediated 
by GlyT1 and GlyT2, and on monoamine transporters (human serotonin (hSERT), 
noradrenaline (hNET) and dopamine (hDAT), demonstrating these compounds are 
selective for L-glutamate transporters (supplementary Figure 3). 
Previous studies of the three-dimensional structure of the EAAT reveal that the 
transporter is divided into two domains: a transport domain containing the substrate 
binding sites, and surrounding it a peripheral rigid scaffold, designated the 
trimerization domain110-111. The trimerization domain provides the interaction interface 
between the three subunits of the trimer and is believed to facilitate the elevator-like 
movement of the inner transport domain112-113. Our previous work suggests that 
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residues at the interface between the transport and the trimerization domains are 
critical for transport stimulation80. Intriguingly, preliminary modeling analysis of the 
three-dimensional structure of the EAAT, searching for residues that are similar in 
EAAT1 and EAAT2 (but different in EAAT3), revealed multiple molecular determinants 
that could be involved in the interaction of compound 12 with transporters EAAT1 and 
EAAT2 (not shown). Therefore, at this point, we are unable to propose a mechanism 
of interaction between compound 12 and EAATs. However, we speculate that the 
compound might be binding to the similar previously identified allosteric site80, and 
possibly accelerating the rate of the transport by facilitating the movement of the 
transport domain, like the recently identified positive allosteric modulators (PAMs) of 
EAAT281-82. Therefore, future studies including additional molecular modeling and 
mutagenesis of key residues are needed to investigate mechanisms of interaction of 
4-OH-IndAc3(Me2)4(Me2)3Arg2+ (12) with the glial transporters. 
Regrettably, other PAMs and negative allosteric modulators (NAMs) of 
transporters with similar structures of 12 are not available to date. However, several 
allosteric modulators of glutamate receptors, such as AMPA, NMDA and metabotropic 
glutamate receptors, have been identified114. For instance, polyamines spermine and 
spermidine act as PAMs of the NMDA receptor to potentiate channel activity. It is 
thought that they act by binding to the amino-terminal domain, resulting in the 
separation of the GluN1R and GluN2R domains and opening of the ion channel114. 
Due to remarkably different functions and mechanisms between these receptors and 
the EAATs, we refrain to suggest any mechanistic similarities of these PAMs and 
compound 12. However, polyamines from spider venoms have been studied for a long 
time, and it is well stablished that many of them act as ionotropic glutamate receptor 
antagonists of the vertebrate and invertebrate central nervous systems115. Some 
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examples include the polyamine toxins Joro spider toxin-3 (JSTX-3) and Nephila 
polyamine toxins-1 and -8 (NPTX-1 and NPTX-8), isolated from the venom of the orb-
weaver spider Nephila clavata (Joro spider). These are very potent open-channel 
blockers of ionotropic glutamate receptors, providing pharmacological tools for studies 
of these receptors116. Likewise, compounds 11 and 12 could be used in the future as 
pharmacological tools to study the molecular scaffolds in the glial transporters that 
they modulate.
Effects of Pwx10 fraction and compound 12 on excitotoxic insults in mixed 
neuron-glia cultures 
We evaluated Pwx10 fraction and the acylpolyamine 4-OH-
IndAc3(Me2)4(Me2)3Arg2+ (12) for neuroprotective effects after prolonged (24 h) 
excitotoxic insults with application of L-glutamate or acute (20 min) insults with oxygen-
glucose deprivation (OGD), in mixed neuron-glia cultures. Our cultures had optimized 
growth conditions to result in ~15% of glia growth in the cultures after 14 DIV82. As 
positive control for neuroprotection, we used APV (DL-2-Amino-5-
phosphonopentanoic acid), an NMDA receptor blocker. We examined the 
neuroprotective potential of these compounds by immunocytochemical analysis, 
comparing MAP-2 expression among different experimental groups, as previously 
described82.
Neuronal survival after L-glutamate insult and treatments with Pwx10 fraction 
and compound 12 
Cultures were grown for 14 DIV before treatments, then subjected to 24h insult 
in presence of vehicle (control), or natural Pwx10 fraction or synthetic compound 12. 
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Figure 9A show representative images of cultures on different conditions. At 
baseline conditions (no L-glutamate insult or compound treatment - vehicle), neurons 
did not display pyknotic nuclei or neurite damage, which are indicators of neuronal 
death117-118. Neurons treated with Pwx10 fraction alone (100 M; 24 h) also resemble 
the baseline vehicle conditions, suggesting that the components in the Pwx10 fraction 
are not neurotoxic. After L-glutamate insult, we observed reduced MAP-2 staining and 
DAPI positive, MAP-2 negative cells, indicators of cell death. On the other hand, 
neurons subjected to acute L-glutamate insult in presence of Pwx10 fraction (100 nM; 
24 h) displayed morphological characteristics similar to baseline vehicle conditions, 
suggesting that this compound is neuroprotective in an excitotoxic environment. 
Total neuronal survival levels from different experimental conditions were 
quantified. Figure 9 B illustrates the neuroprotective effects of both Pwx10 fraction and 
compound 12, following the application of 100 µM L-glutamate insult in 14 DIV mixed 
neuron-glia cultures. Application of 100 µM L-glutamate significantly decreased 
neuronal survival to 25.9 ± 15.4% of baseline vehicle levels (red bar). Only application 
of 100 nM Pwx10 fraction or 12 after L-glutamate insult resulted in a significant 
neuroprotective effect, increasing survival levels to 70.5 ± 13.4 (Pwx10 fraction) and 
64.4 ± 0.5% (12) of baseline whereas 1 nM and 10 nM of the Pwx10 fraction did not 
increase neuronal survival compared to the insult condition. To determine if the 
neuroprotective effect of 4-OH-IndAc3(Me2)4(Me2)3Arg2+ requires an active L-
glutamate transporter, we subjected mixed cultures to prolonged L-glutamate insult, 
followed by co-treatment with 100 nM Pwx10 fraction and the L-glutamate transport 
inhibitor TBOA (100 µM), that inhibits all transporter subtypes at this concentration, 
and with the selective EAAT2 inhibitor WAY 213613 (1 µM). Co-treatment of 100nM 
of Pwx10 fraction with both L-glutamate transport blocker TBOA and EAAT2 specific 
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inhibitor WAY 213613 abolish the neuroprotective effect of the compound. Co-
treatment with TBOA results in a more significant knockdown of the neuroprotective 
effects of Pwx10 fraction compared to co-treatment with WAY 213613, which is 
consistent with our findings that the Pwx10 fraction increases L-glutamate uptake 
through both EAAT1 and EAAT2. Finally, treatment with positive control APV results 
in significant neuroprotection, with survival at 80.7 ± 2.7% of baseline, confirming the 
viability of our cultures, and suggesting that excessive L-glutamate transmission 
through the NMDA receptor plays a crucial role in L-glutamate excitotoxicity and 
neuronal death119-120, thus providing a positive control to measure the effect of the 
active compound in the Pwx10 fraction. 
To better understand the contribution of the different subtypes of EAATs in the 
mixed neuron-glia system, L-glutamate uptake assays in presence of several inhibitors 
were performed. Supplementary Figure 3 indicates that L-glutamate uptake in 
presence of 1 M WAY 213613 inhibits 50 ± 5% of L-glutamate uptake. At this 
concentration, this inhibitor is selective for EAAT2 inhibition over EAAT1 and EAAT3, 
indicating that ~ 50% of the transporters in this approach are EAAT2. On the other 
hand, UCPH-101, at 1 M, a concentration that displays a selective inhibition of 
EAAT1 over the other subtypes, inhibits 23 ± 8% of L-glutamate uptake, suggesting 
that ~25% of the transporters in this system are comprised of EAAT1. When co-
incubated with both inhibitors, the transport is inhibited to a level of 6.5 ± 0.5%, 
indicating the L-glutamate uptake in these cultures is mediated by EAAT1 and EAAT2, 
with a small percentage of uptake probably due to EAAT3. 
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Neuronal survival after Oxygen Glucose Deprivation (OGD) insult and Pwx10 
fraction and compound 12 treatments 
In these studies, we also evaluate Pwx10 and 4-OH-IndAc3(Me2)4(Me2)3Arg2+ 
(12) in an in vitro stroke model, by subjecting the cultures to OGD insults. Figure 10 A 
shows representative images of vehicle (control) cultures, under OGD conditions, and 
under OGD followed by treatment with 100 nM Pwx10 fraction. As seen above, vehicle 
(control) cultures do not display pyknotic nuclei or neurite damage, as opposed to 
OGD-treated cultures, in which there is a reduction in MAP-2 staining and DAPI 
positive, MAP-2 negative cells, indicators of cell death. On the other hand, neurons 
subjected to OGD insult followed by incubation of Pwx10 fraction (100 nM; 24 h) 
displayed morphological characteristics like baseline vehicle conditions, suggesting 
that this compound is neuroprotective in an excitotoxic environment. The 
quantification, showed in Figure 10 B, illustrates that the Pwx10 fraction and 
compound 12 displayed neuroprotective effects following 20 minutes of OGD. 
Application of 10nM and 100 nM Pwx10 fraction and acylpolyamine 12 following the 
OGD insult significantly increasing neuronal survival from 29.5 ± 9.6% of baseline to 
70.4 ± 9.6% and 78.7 ± 4.2%, respectively. Intriguingly, the concentration of 10 nM 
Pwx10 fraction was able to confer neuroprotection in this OGD model, unlike following 
L-glutamate insults, where only 100 nM was effective. Future experiments determining 
extracellular concentration of L-glutamate in both models could help examine the 
discrepancy in effectiveness between the models. Pwx10 fraction at 1nM does not 
display significant neuroprotective effects, only increasing neuronal survival to 49.7 ± 
21.6% compared to the control condition. Synthetic compound 12 at 100 nM displays 
similar neuroprotective effects compared to the natural compound, increasing 
neuronal survival to 89.3 ± 23.9%. Co-administration with TBOA and WAY 213613 
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both result in no increases in neuronal survival, and this indicates again that the 
neuroprotective effects of 4-OH-IndAc3(Me2)4(Me2)3Arg2+ (12) from OGD-induced 
injury is due to modulation of L-glutamate transporters. 
Previous studies evidence that L-glutamate excitotoxicity plays an essential role 
in the neurodegeneration observed following ischemic stroke and key elements 
involved in excitotoxicity121, like L-glutamate transport, may serve as potential targets 
for neuroprotection after ischemic stroke. In this study, we have shown that 4-OH-
IndAc3(Me2)4(Me2)3Arg2+ (12) was neuroprotective in this model of in vitro insult. It is 
important to note that under ischemic conditions, an increase in extracellular L-
glutamate can happen by reversal of uptake122-123. However, upon cessation of the 
insult, it has been shown that L-glutamate transport activity recovers124. We speculate 
that 4-OH-IndAc3(Me2)4(Me2)3Arg2+ (12) is still able to accelerate the removal of L-
glutamate to restore homeostasis during the 24h recovery time period following the 
insult. This concept is supported by previous work with EAAT2 expression enhancers, 
including ceftriaxone and riluzole, that offer significant protection of neuron tissues 
against ischemic excitotoxicity19, 125-128. In future studies, we plan to determine the L-
glutamate concentration in culture media after insult and compound treatments to 
complement and strengthen the notion that the mechanism of 4-OH-
IndAc3(Me2)4(Me2)3Arg2+ (12) is through increased EAAT1/EAAT2 activity resulting 
in increased L-glutamate clearance. Additionally, future studies will determine whether 
NMDA, AMPA and kainate glutamate receptors modulation is involved, as inhibition of 
these could result in neuroprotection (as seen in our assays with APV, an NMDA 
receptor blocker). We will also examine whether metabotropic L-glutamate receptors 
modulation is involved in the action of compound 12 on transporters, as these 
receptors can exert different actions (toxic or compensatory) in response to excitotoxic 
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stimuli129. Future studies will also investigate whether apoptosis is occurring, and 
which intracellular signalling pathways are involved in the insult models. 
Conclusions 
In this work, we attempted to elucidate the chemical structures of compounds with 
intriguing and promising biological activities that are part of three HPLC fractions that 
were collected from the venom of P. bistriata spiders, namely Pwx1, Pwx2 and Pwx10. 
Furthermore, we have shown that the P. bistriata venom contains 36 acylpolyamines 
with and without amino acid linkers in their structures, a unique finding as both types 
of substances were never found coexisting in a spider venom until now. In addition, 
the presence of nucleosides and other small compounds such as amino acids free 
polyamines and quaternary amines was shown. Regrettably, our approach did not 
yield the identification of the chemical structure of the active substance in the Pwx1 
fraction. Nonetheless, previous studies used this fraction to identify the region of L-
glutamate transporter EAAT2 responsible for transport stimulation80. This important 
knowledge was used to identify novel compounds that were shown to be positive 
allosteric modulators of EAAT281. We speculate that one or several unknown minor 
active components, have, at least in part, a similar structure of these allosteric 
modulators. We consider that the identification of novel positive allosteric modulators 
(PAMs) of EAAT2 holds promise to further drug development and to further our 
understanding of allosteric modulation of L-glutamate transporters. 
Regarding the compound found at m/z 175.2 in the Pwx2 fraction, we could not 
confirm the presence of the previously proposed structure 2-amino-5-
ureidopentanamide (FrPbAII) in P. bistriata venom, but the amino acid arginine. 
Unfortunately, neither arginine nor any of the additional constituents (betaine, 
Page 29 of 81































































homarine, L-carnitine hydrochloride, spermidine, or spermine) acted like the Pwx2 
fraction, which is as a weak inhibitor of GABA uptake through selective modulation of 
GAT-1. We speculate that this activity is either due to an unknown minor component 
of the fraction or to unknown synergistic effects among different molecules within the 
venom. 
Regarding the Pwx10 fraction, we successfully identified its major component to 
be an acylpolyamine with the chemical structure 4-OH-IndAc3(Me2)4(Me2)3Arg2+ (12). 
Subsequently, compound 12 and analogue 11 were synthesized and we further 
confirmed their biological activity in neurotransmitter uptake assays. 
Additionally, the compounds displayed neuroprotective properties after in vitro 
excitotoxic insults, an effect that was abolished in presence of L-glutamate transport 
inhibitors, suggesting dependence of active L-glutamate transporters. Strikingly, since 
mixed neuron-glia culture approach we used has ~15% of glia82, we speculate that the 
neuroprotective effects of this class of compounds in vivo, where the proportion of glia 
to neurons is at least 1:1 and has been suggested to be as high as 10:1 130, would be 
amplified. Indeed, previous studies revealed the Pwx10 fraction to be neuroprotective 
after intracerebral ventricular administration in two in vivo epilepsy models78-79. When 
considering potential future translational studies, it is worth noting the activity of 
compound 12 on EAAT1 and EAAT2 is desirable, as targeting astrocytic glutamate 
transporters over neuronal transporters may be beneficial over activation of neuronal 
transporters, such as EAAT3 and EAAT4. After clearance into astrocytes by EAAT1 
and EAAT2, glutamate is converted to glutamine, which is exported to neurons and 
re-converted to glutamate131, contributing to the glutamate-glutamine cycle pathway 
for recycling of neurotransmitter pools of glutamate58, 132. Furthermore, allosteric 
modulation is likely better suited to maintaining the highly precise temporal and spatial 
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aspects of glutamatergic synaptic transmission114. On the other hand, neuronal 
transporters EAAT3 and EAAT4 are localized to the postsynaptic neuron near NMDA, 
AMPA, and kainate receptors and metabotropic glutamate receptors (mGluR), such 
as mGluR5, and their modulation could lead to receptor activation and may have 
unwanted liabilities as a consequence of downstream signaling 133-134. 
However, we have not studied this compound for its pharmacokinetic exposure in 
vivo either in plasma or in the CNS. Polycationic compounds may be toxic due to their 
propensity to accumulate in tissue or in mitochondria. Due to the peptidic nature of the 
compound, it is predicted to be metabolically unstable in vivo, although this needs to 
be confirmed. Additionally, synthesizing the compound on scale would require 
significant efforts, since it involves a multistep synthesis and the resulting highly polar 
product required HPLC purification (Schemes 1 and 2). Hence, compound 12 seems 
to be a good tool compound for proof of concept studies, as drug development 
progression studies are unlikely. 
It is well known that L-glutamate excitotoxicity is implicated in a wide range of CNS 
disorders, such as TBI, epilepsy and chronic neurodegenerative diseases. Safe and 
effective pharmacological approaches to treat patients after excitotoxic events are 
urgently needed. This study offered proof of concept of the neuroprotective properties 
of 4-OH-IndAc3(Me2)4(Me2)3Arg2+ (12). We conclude that acylpolyamines, as well 
previously identified EAAT2 PAM compounds, provide a starting point for identification 
of a new class of neuroprotective compounds that function by enhancing the removal 
of excessive L-glutamate in the synaptic cleft and preventing L-glutamate-mediated 
excitotoxicity.
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UHPLC grade H2O (< 5ppb) was obtained by purification of deionized H2O with a MilliQ 
gradient apparatus (Millipore, Milford, MA, USA). Acetonitrile (MeCN) was obtained 
from Fluka (LC-MS grade, Buchs, Switzerland) and trifluoroacetic acid (TFA) from 
Biosolve (Valkenswaard, Netherland). The reference chemicals were purchased from 
the companies as indicated: L-isoleucine, L-leucine, L-phenylalanine, spermine 
hydrochloride, spermidine, serotonin hydrochloride and D-pantothenic acid Calcium 
salt (Fluka, Buchs, Switzerland), L-tryptophan (Merck, Darmstadt, Germany), D-
tyrosine (Novabiochem Merck, Darmstadt, Germany), betaine (Acros Chemie 
Brunschwig, Switzerland), adenosine, guanosine, inosine, L-carnitine hydrochloride, 
O-acetyl-L-carnitine and propionyl-L-carnitine (Sigma-Aldrich, Buchs, Switzerland). 
Commercial FrPbAII was purchased from Enzo Life Sciences (Farmingdale, NY, 
USA). 
Homarine was synthesized according to literature135. The chemicals used for 
synthesis, methyl iodide, 2-pyridinecarboxylic acid, propylene oxide, diethyl ether and 
methanol, were obtained from Sigma-Aldrich (Buchs, Switzerland).
Natural Pwx2 fraction was isolated from the venom of P. bistriata spider according to 
previous methodology73. Natural Pwx10 fraction was purified as described by 76.
Non-radiolabelled L-glutamate and compounds arginine and nipecotic acid were 
purchased from Millipore-Sigma (Billerica, MA, USA). Compounds (2R)-amino-5-
phosphonovaleric acid (APV), DL-threo-β-Benzyloxyaspartic acid (DL-TBOA), WAY 
213613, sarcosine and N-Arachidonylglycine were purchased from Tocris (Bristol, 
United Kingdom). 
Transfection reagent TransIT-LT1 was from Mirus Bio LLC (Madison, WI, USA).
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Radiolabelled substrates, [3H]-glutamic acid (51.1 Ci/mmol), [3H]-glycine (48.7 
Ci/mmol), [3H]-GABA (92.1 Ci/mmol), [3H]-dopamine (53.6 Ci/mmol), [3H]-serotonin 
(28.2 Ci/mmol), [3H]-norepinephrine (14.9 Ci/mmol), were purchased from Perkin 
Elmer (Boston, MA, USA). 
For cell lines, culture media, including Dulbecco’s modified Eagle’s medium (DMEM) 
with glucose, fetal bovine serum, penicillin/streptomycin and blasticidin were obtained 
from Thermo Fisher Scientific (Waltham, MA, USA).
Scintillation fluid was obtained from Thermo Fisher Scientific (Waltham, MA, USA). 
For primary cultures, cell culture media including Neurobasal medium with pyruvate, 
glucose-free Dulbecco’s Modified Eagle Medium (DMEM, OGD media), glutamine, 
gentamicin, HEPES (1 M), B27, Poly-L-lysine and DNase were purchased from 
Sigma-Aldrich (St. Louis, MO, USA). Neurobasal-A, glutamine and B-27 supplement 
were obtained from Thermo Fisher Scientific (Waltham, MA, USA). Fetal bovine serum 
and horse serum were purchase from Hyclone (South Logan, UT, USA). 
Poly-lysine coated 96-well plates and phosphate-buffered saline (D-PBS) were 
purchased from Corning (Corning, NY, USA).
Tools for animal dissection was purchased from Biomedical Research Instruments 
(Silver Spring, MD, USA). 
General Chemistry
All reactions were conducted under an inert gas atmosphere (nitrogen or argon) using 
a Teflon-coated magnetic stir bar at the temperature indicated. Commercial reagents 
and anhydrous solvents were used without further purification. Removal of solvents 
was conducted by using a rotary evaporator, and residual solvent was removed from 
nonvolatile compounds using a vacuum manifold maintained at approximately 1 Torr. 
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All yields reported are isolated yields. Preparative reversed-phase high pressure liquid 
chromatography (RP-HPLC) was performed using a Gilson GX-271 semi-prep HPLC, 
eluting with a binary solvent system A and B using a gradient elusion (A, H2O with 
0.1% trifluoroacetic acid (TFA); B, CH3CN with 0.1% TFA) with UV detection at 220 
nm. Low-resolution mass spectral (MS) data were determined on an Water Acquity 
QDa LCMS mass spectrometer with UV detection at 254 nm. 1H NMR spectra were 
obtained on a Bruker Avance II 400 (400 MHz) spectrometer. Chemical shifts (δ) are 
reported in parts per million (ppm) relative to residual undeuterated solvent as an 
internal reference. The following abbreviations were used to explain the multiplicities: 
s = single; d = doublet, t = triplet, q = quartet, dd = doublet of doublets, dt = doublet of 
triplets, m = multiplet, br = broad.
Spider collection and preparation of the venom extract
The P. bistriata spiders were collected according to the Brazilian Chico Mendes 
Institute for the Biodiversity Conservation (ICMBio- SISBIO protocol No. 46797) by the 
group of Ferreira dos Santos at Ponta Grossa (Paraná state, Brazil) and Marília, (São 
Paulo state, Brazil) and stored in dry ice. The species was identified by Professor W. 
Ferreira dos Santos. The crude venom glands from P. bistriata spiders were extracted 
in H2O/MeCN 9:1 (gland/solvent 1:5 [m/v]), centrifuged (10,621× g; 10 min; 4 °C) and 
the supernatant was lyophilized, and weighed. To remove large proteins, the venom 
extract was again dissolved in H2O/MeCN 9:1 and filtered (Amicon Ultra – 0.5mL 
Centrifugal Filters 3,000 NMWL (Millipore, Milford, MA, USA), 14,000 rpm, 4 °C). The 
filtered solution was lyophilized. For UHPLC analysis the venom was dissolved in 
H2O/MeCN 9:1 + 0.05 % TFA at 10 µg µl-1. All reference compounds were dissolved 
in H2O/MeCN 9:1 at 10 g ml-1. The samples were stored at -20 oC prior to use.
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UHPLC-MS and MS/MS 
The UHPLC separations were performed on a Dionex UltiMate 3000 HPLC 
instrument (Thermo Scientific, Germering, Germany) equipped with an autosampler, 
a pump and a diode-array detector (DAD) of the same producer series. The samples 
were chromatographed at a flow rate of 0.30 ml min-1 on a RP-C18+ column (CortecsTM 
UPLC® C18+ 1.6 μm, 2.1x150 mm, Waters, Milford, MA, USA) with solvents A and B 
consisting of H2O + 0.05% TFA and MeCN/H2O 8:2 [v/v] + 0.05% TFA, respectively. 
The column chamber temperature was set to 25 °C. The samples were injected at a 
volume of 1 μl. The strong wash was MeOH and weak wash H2O/MeCN 95:5 [v/v]. 
The gradient went from 3.8 to 25% of eluent B over 22 min. Finally, the column was 
regenerated at 100% B for 4 min and equilibrated at 3.8% B over 6 min.
The UHPLC system was connected to a QExactive Orbitrap FT high-resolution 
mass spectrometer (Thermo Scientific, Waltham, MA, USA) equipped with an HESI 
source. The MS conditions were: sheath gas flow rate (N2, 48), aux gas flow rate (N2, 
11), aux gas heater temperature (320 °C) and sweep gas flow rate (N2, 2), spray 
voltage (3.5 kV), S-lens RF level (55), capillary temperature (256 °C). Full scan MS 
were performed in positive ion mode at 70’000 resolutions and was between m/z 100 
to 1500. The AGC target setting for full scan MS experiment was set to 106 with a 
maximum of 30 injection times. The mass spectrometer was calibrated for mass 
accuracy once a day according to the manufacturer’s instructions. The relative mass 
error being typically lower than 2 ppm (externally).
The MS/MS experiments were acquired in Full MS/ddMS2 (Top N) mode with a 
maximum of five ions to trigger after one survey scan. The resolving power was set to 
17’500. The acquisition was performed with an isolation window set to 0.8 m/z. The 
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AGC target setting was set to 105. The normalized collision energy (NCE) was set to 
a gradient (30, 35, 40). The MS/MS spectra were recorded of the top five ions.
H/D exchange experiment 
On-line H/D exchange was done on the same instrumental set up. For the 
chromatography, the solvents A and B consisted of D2O + 0.05% d1-TFA and 
MeCN/D2O 8:2 [v/v] + 0.05% d1-TFA, respectively. The column chamber temperature 
was set to 40 °C. The chromatogram was recorded in FS-MS mode only (no MS/MS 
data recorded). All other parameters remained the same. 
Synthesis of 4-OH-IndAc3(Me2)4(Me2)3Arg2+ (12)
Schemes 1-2 show the synthesis of 4-OH-IndAc3(Me2)4(Me2)3Arg2+ (12). 
(S, Z)-Tert-butyl 2, 17, 17-trimethyl-7,15-dioxo-16-oxa-2, 6, 12, 14-
tetraazaoctadecan-8-yl-13-ylidenedicarbamate (3):
N1,N1-dimethylpropane-1,3-diamine (1) (129 mg, 1.26 mmol) and (Z)-5-(2,3-bis(tert-
butoxycarbonyl)guanidino)-2-(tert-butoxycarbonylamino) pentanoic acid (2) (500 mg, 
1.05 mmol) were combined  in 20 mL of dry CH2Cl2 at 0 oC with stirring. Then 
diisopropylethylamine (0.75 mL, 4.18 mmol) was added followed by the dropwise 
addition of 50% solution of T3P in CH2Cl2 (871 mg, 1.37 mmol). The reaction mixture 
was then stirred for 1h at 0 o C. Completion of the reaction was confirmed by LC-MS, 
then the reaction mixture was quenched with water and the product was extracted with 
CH2Cl2 and dried over anhydrous Na2SO4. After filtration the solvent was evaporated 
under reduced pressure to obtain the crude product residue which was purified by 
silica gel flash column chromatography to afford the title compound 3 (496 mg, 84%) 
as a white solid. The product was confirmed by 1H NMR & MS.
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1H NMR (400 MHz, CDCl3): δ 11.46 (1H, s), 8.36 (1H, t, J=4.9 Hz), 7.53 (1H, s), 5.40 
(1H, d, J=7.2 Hz), 4.18-4.02 (1H, m), 3.54-3.26 (4H, m), 2.49-2.38 (2H, m), 2.28 (6H, 
s), 1.92-1.78 (1H, m), 1.74-1.57 (5H, m), 1.498 (9H, s), 1.490 (9H, s), 1.44 (9H, S). 
MS: m/z 581 ([M+Na]+). 
Methyl 2-(4-methoxy-1H-indol-3-yl)-2-oxoacetate (5):
To a stirred solution of 4-methoxy-1H-indole (4) (5.0 g, 33.97 mmol) dissolved in 100 
mL of anhydrous THF at 0 o C, was added oxalyl chloride (4.74 g, 37.34 mmol) 
dropwise, then the reaction mixture was allowed to stir for 2h at room temperature. 
The reaction mixture was then cooled to 0 oC, and 5 mL of MeOH was added dropwise. 
Then the reaction mixture was stirred overnight at room temperature.Formation of the 
product was confirmed by LC-MS. The reaction mixture was diluted with diethyl ether, 
dried over sodium sulfate, filtered and evaporated under reduced pressure to afford 
the desired compound 5 (3.98 g, 50.2%) as a colorless solid. The product was 
confirmed by 1H NMR & Mass Spec. 
1H NMR (400 MHz, DMSO-d6): δ 12.37 (1H, s), 8.19 (1H, s), 7.20-7.10 (2H, m), 6.73 
(1H, d, J=7.8 Hz), 3.84 (3H, s), 3.82 (3H, s). MS: m/z 234 ([M+ H]+).
Methyl 2-(4-methoxy-1H-indol-3-yl) acetate (6):
To a stirred room temperature solution of methyl 2-(4-methoxy-1H-indol-3-yl)-2-
oxoacetate (5) (3.98 g, 17.0 mmol) in 100 mL of dioxane/ H2O (2:1) was added 10% 
palladium on activated carbon (1.6 g, 15.0 mmol) and sodium hypophosphite 
monohydrate (18.18 g, 171.52 mmol) simultaneously. Then the mixture was stirred for 
48 h at room temperature. Completion of the reaction was confirmed by LC-MS. Then 
the reaction mixture was diluted with 60 mL of H2O and filtered through a celite pad. 
The aqueous mixture was then extracted with ethyl acetate and dried over anhydrous 
Na2SO4. The solvent was evaporated under reduced pressure to provide a crude 
Page 37 of 81































































residue which was purified by silica gel flash column chromatography to afford the title 
compound 6 (2.3 g, 61.5%) as a white solid. The product was confirmed by NMR & 
MS. 
1H NMR (400 MHz, CDCl3): δ 8.04 (1H, s), 7.06 (1H, t, J=8.0 Hz), 6.97-6.90 (2H, m), 
6.46 (1H, d, J=7.9 Hz), 3.94 (2H, s), 3.86 (3H, s), 3.71 (3H, s). MS: m/z 220 ([M+ H]+).
2-(4-Methoxy-1H-indol-3-yl) acetic acid (7):
To a stirred solution of methyl 2-(4-methoxy-1H-indol-3-yl) acetate (6) (2.3 g, 10.49 
mmol) in 90 mL of THF/H2O (2:1) at 0 oC was added KOH (1.76 g, 31.49 mmol) and 
the reaction mixture was allowed to warm to room temperature and stirred for 6h. 
Completion of the reaction was confirmed by LC-MS. Then volatiles were evaporated 
under reduced pressure and the crude product was neutralized with 1N HCl (aq). The 
obtained product was washed with water and dried under vacuum to afford the title 
compound (7) (1.82 g, 84.5%) that was confirmed by NMR & MS. 
1H NMR (400 MHz, DMSO-d6): δ 11.90 (1H, s), 10.81 (1H, s), 7.02 (1H, d J=2.5 Hz), 
6.98-6.89 (2H, m), 6.41 (1H, dd, J=7.0 Hz, 1.4 Hz), 3.78 (3H, s), 3.73 (2H, s). MS: m/z 
206 ([M+ H]+).
N-(3-(Dimethyl amino) propyl)-2-(4-methoxy-1H-indol-3-yl) acetamide (8):
To a stirred solution of 2-(4-Methoxy-1H-indol-3-yl) acetic acid (7) (825 mg, 2.85 mmol) 
and N1,N1-dimethylpropane-1,3-diamine (1) (821 mg, 8.034 mmol) in 20 mL dry 
CH2Cl2 at 0 oC, (2.16 mL, 12.0 mmol) was added diisopropylethylamine (1.84 mL, 
14.25 mmol) and T3P 50% solution in CH2Cl2 by weight (3.32g , 3.70 mmol) 
simultaneously by dropwise addition. Then the reaction mixture was stirred at 30 mins 
at 0 oC. The completion of the reaction was confirmed by LC-MS, after which the 
reaction mixture was quenched with cold water, and extracted with CH2Cl2, then dried 
over anhydrous Na2SO4, and the solvent was evaporated under reduced pressure. 
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The crude product was purified by flash column chromatography to afford the title 
compound (8) (890 mg, 76.5%) that was confirmed by NMR & MS. 
1H NMR (400 MHz, DMSO-d6): δ 10.85 (1H, s), 7.41 (1H, t, J=5.4 Hz), 7.0 (1H, d, 
J=2.2 Hz), 6.98-6.89 (2H, m), 6.42 (1H, dd, J=6.8 Hz, 1.7 Hz), 3.80 (3H, s), 3.58 (2H, 
s), 3.11-3.01 (2H, m), 2.12 (2H, t, J=7.0 Hz), 1.96 (6H, s), 1.54-1.40 (2H, m). MS: m/z 
290 ([M+ H]+).
4-Iodo-N-(3-(2-(4-methoxy-1H-indol-3-yl) acetamido) propyl)-N, N-
dimethylbutan-1-aminium iodide (9):
To a stirred solution of N-(3-(Dimethyl amino) propyl)-2-(4-methoxy-1H-indol-3-yl) 
acetamide (8) (600 mg, 2.073 mmol) in 10 mL of butyronitrile at room temperature was 
added 1,4-diiodobutane (6.42 g, 20.71 mmol). The temperature of the reaction mixture 
was then raised to 50 oC and stirred for 16 h. Completion of the reaction was confirmed 
by LC-MS. The reaction mixture was then diluted with 50 mL diethyl ether, and the 
resulting precipitate was filtered and washed with diethyl ether to obtain the title 
compound (9) (890 mg, 71.5%) that was confirmed by NMR & MS. 
1H NMR (400 MHz, CD3OD): δ 7.12-6.97 (3H, m), 6.56 (1H, d, J=7.0 Hz), 3.90 (3H, 
s), 3.80 (2H, s), 3.36-3.25 (2H, m), 3.20 (2H, t, J=6.96 Hz), 3.12-2.98 (4H, m), 2.86 




To a stirred solution of 4-Iodo-N-(3-(2-(4-methoxy-1H-indol-3-yl)acetamido)propyl)-
N,N-dimethylbutan-1-aminium iodide (9) (800 mg, 1.33 mmol) in 15 mL of ethanol was 
added (S, Z)-Tert-butyl 2,17,17-trimethyl-7,15-dioxo-16-oxa-2,6,12,14-
tetraazaoctadecan-8-yl-13-ylidenedicarbamate (3) (745 mg, 1.33 mmol) at room 
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temperature and reaction temperature was raised to 45 oC and stirred for 48 h. 
Completion of the reaction was confirmed by LC-MS. Volatiles were removed under 
reduced pressure to obtain crude product that was purified by reverse phase HPLC to 
afford the title compound (10) (1.2 g, 61.2%) confirmed by NMR & MS. 
1H NMR (400 MHz, CD3OD): δ  7.14-7.0 (3H, m), 6.56 (1H, dd, J=7.0 Hz, 1.2 Hz), 
3.98 (1H, m), 3.94 (3H, s), 3.76 (2H, s), 3.40-3.23 (8H, m), 3.2-3.16 (2H, m), 3.15-3.05 
(4H, m), 3.02 (6H, s), 2.91 (6H, s), 2.0-1.85 (4H, m), 1.84-1.59 (8H, m), 1.56 (4H, s), 
1.53 (9H, s), 1.44 (14H, s). MS: m/z 452 (M2+).
(S)-N1-(3-(2-amino-5-guanidino pentanamido) propyl)-N4-(3-(2-(4-methoxy-1H-
indol-3-yl) acetamido) propyl)-N1, N1, N4, N4-tetramethylbutane-1,4-diaminium 
iodide (11):
To a stirred solution of (S,Z)-N1-(6,11-bis(tert-butoxycarbonylamino)-2,2-dimethyl-
4,12-dioxo-3-oxa-5,7,13-triazahexadec-5-en-16-yl)-N4-(3-(2-(4-methoxy-1H-indol-3-
yl)acetamido)propyl)-N1,N1,N4,N4-tetramethylbutane-1,4-diaminium (10) (60 mg, 
0.052 mmol) in 2 mL dry CH2Cl2 at 0 oC, was added 2 mL of trifluoroacetic acid  
dropwise, then the reaction mixture was allowed to warm to room temperature and 
was stirred for 16h. Completion of the reaction was confirmed by LC-MS. Volatiles 
were removed under reduced pressure to obtain crude product that was purified by 
reverse phase HPLC to yield compound 11 (30 mg, 0.03 mmol, 67.2% %) that was 
confirmed by NMR & MS. 
1H NMR (400 MHz, CD3OD): δ 7.13-7.0 (3H, m), 6.56 91h, dd J=7.1 Hz, 1.2 Hz), 3.93 
(3H, s), 3.92-3.87 (2H, m), 3.76 (2H, s), 3.50-3.07 (14H, m), 2.07-1.81 (8H, m), 1.75-
1.58 (4H, m). MS: m/z 302 (M2+)..
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N1,N1,N4,N4-tetramethylbutane-1,4-diaminium (10) (30 mg, 0.026 mmol)  in 2 mL 
anhydrous CH2Cl2 at -78 oC, was added 0.2 mL of BBr3 dropwise and slowly, then the 
reaction mixture was gradually brought to room temperature over 1-2 hours and stirred 
for 16h. Completion of the reaction was confirmed by LC-MS. Volatiles were removed 
under reduced pressure to provide the crude product, 12. Then 1 mL of MeOH was 
added slowly and dropwise at -78 oC and the mixture was slowly brought to room 
temperature. The crude product was purified by reverse phase HPLC to obtain the title 
compound (12) (10 mg, 0.012 mmol, 45.6%) that was confirmed by NMR & MS. 
1H NMR (400 MHz, CD3OD): δ 7.05 (1H, s), 7.0-6.9 (2H, m), 6.44 (1H, dd, J=7.0 Hz, 
1.5 Hz), 3.95-3.87 (2H, m), 3.75 (2H, s), 3.5-3.05 (14H, m), 2.06-1.82 (8H, m), 1.76-
1.54 (4H, m). MS: m/z 295 (M2+).
Rodent animals
All animal experiments were treated according to the guidelines for use of 
animals in research approved by the Drexel University Institutional Animal Care and 
Use Committee (IACUC) and are in agreement with the U.S. Public Health Service 
Policy on Humane Care and Use of Laboratory Animals. Sprague-Dawley rats were 
purchased from Charles River (Malvern, PA, USA), and housed in Association for 
Assessment and Accreditation of Laboratory Animal Care-accredited facilities. Animal 
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housing and experimental procedures were also approved by the Drexel University 
College of Medicine Institutional Animal Care and Use Committees (IACUC). 
Antibodies
Primary antibodies for immunocytochemistry were polyclonal anti-microtubule 
associated protein-2 (MAP-2, cat: AB5622) and monoclonal anti-glial fibrillary acidic 
protein (GFAP, cat: MAB360), both purchased from Millipore (Temecula, CA, USA). 
Secondary antibodies included Alexa Fluor® 488 conjugated AffiniPure Donkey Anti-
Rabbit IgG and Cy™3-conjugated AffiniPure Donkey Anti-Mouse IgG. These 
antibodies, along with normal donkey serum and normal goat serum, were purchased 
from Jackson Immuno Research (West Grove, PA, USA).
Examination of effect of compounds in neurotransmitter uptake assays
Neurotransmitter transporter studies in cell lines
Cell Culture and DNA Transfection. COS-7 cells were maintained in DMEM 
containing 10% fetal bovine serum, 100 units/mL of penicillin and 100 µg/mL 
streptomycin in a humidified incubator with 5% CO2 at 37 °C. MDCK cells were kept 
under the same conditions except that DMEM media contained 1 g/mL blasticidin as 
well. 
For L-glutamate, GABA and glycine uptake assays, subconfluent COS-7 cells 
were transiently transfected with 0.5 g of plasmid DNA (EAAT1, EAAT2, EAAT3, 
GAT-1, GAT-3, GlyT1 and GlyT2) per well using TransIT-LT1 transfection reagent 
(Mirus Bio LLC, Madison, WI, USA), and plated at a density of 50,000 cells/well and 
uptake experiments were performed two days after plating. Transfection with empty 
vector pCMV-5 was used to control for the level of endogenous uptake of radiolabelled 
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substrate in each experimental condition. Additionally, background for GABA uptake 
assays was examined in using nipecotic acid, and for glycine uptake assays using 
sarcosine and N-arachidonylglycine. 
For monoamine transporters assays, stable MDCK cells expressing hNET 
(human noradrenaline transporter), hDAT (dopamine transporter) and hSERT 
(serotonin transporter) were used. Naïve MDCK cells were used for obtaining the 
background. Cells were plated in 96-well plates at density of 50,000 cells/well and 
uptake experiments were performed one day after plating. 
Dose-response assays. Neurotransmitter uptake assays were performed as 
previously reported81, 136. Briefly, cells were washed with room temperature phosphate 
buffer PBS-CM (2.7 mM KCl; 1.2 mM KH2PO4, 138 mM NaCl; 8.1 mM Na2HPO4, 
added 0.1 mM CaCl2 and 1 mM MgCl2, pH 7.4) and incubated for 10 min at 37 oC with 
several concentrations of compounds: Pwx2 fraction or commercial FrPbAII (1 - 500 
µM), arginine, betaine, homarine, L-carnitine hydrochloride, spermidine 
trihydrochloride and spermine (0.01 nM- 100 µM), natural Pwx10 fraction or synthetic 
(compounds 10 and 12 in figures 7-8), at 0.1 –1 mM final concentrations. Uptake 
reactions were initiated by the addition of appropriate radiolabelled substrate (3H-L-
glutamate, GABA or glycine) at final concentration of 50 nM. After 10 min, uptake was 
terminated by removal of solution, followed by two washes with PBS-CM and lysis with 
1% SDS/0.1 M NaOH for 20 min. The lysate was transferred to scintillation vials 
containing 3 mL of scintillation fluid (ScintiVerse, Fisher Scientific, Pittsburgh, PA, 
USA) and radioactivity was quantified in a scintillation counter LS 6500 (Beckman 
Coulter, Brea, CA).
For monoamine transport assays in MDCK cells plated in 96-well plates, we 
used 3H- serotonin or dopamine at 50 nM final concentration. Uptakes were performed 
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similarly as above, expect that an Elx50® Biotek plate washer (Winooski, VT, USA) 
was used for washes. After termination of uptakes, scintillation fluid was added to each 
well, and the plates were counted in a Wallac M50 microbeta scintillation analyser 
(Perkin Elmer, Boston, MA, USA). 
Kinetic assays. For kinetic assays, COS-7 cells were transfected with wild type 
(WT) EAAT1, EAAT2 or empty vector, as described above. Two days later, plates 
were pre-incubated with Pwx10 fraction or compounds 11 and 12 (figures 7-8) for 10 
min at the indicated concentrations. Uptake reactions were initiated by the addition of 
unlabelled L-glutamate and 3H-L-glutamate (1–1000 M, final concentration, 99% 
unlabelled and 1% labelled). After 10 minutes, uptake was terminated and radioactivity 
counted as above.
Glutamate transporter studies in astrocytes 
Astrocyte preparation. Glia was prepared and cultured according a previous 
study108, with modifications. Briefly, cerebral cortices from 2-4 day old Sprague-
Dawley rat pups were dissected under sterile conditions and placed in 60 mm dishes 
containing dissection medium (in mM: Glucose 16, Sucrose 22, NaCl 135, KCl 5, 
Na2HPO4 1, KH2PO4 0.22, HEPES 10, pH 7.4, Osmolarity 310+10 mOsm). Tissue was 
minced with curved scissors, digested in 0.25% trypsin for 15 min. Trypsin action was 
ended by transferring tissue pieces to another vial with dissection medium. Tissue was 
then repeatedly passed through a serological plastic pipette until dissociated by 
trituration in presence of 60 µg/mL DNAse. Cells were pelleted by centrifugation for 
15 minutes at 280 x g, and resuspended in glia plating medium (90% DMEM, 10% 
FBS and 50 g/mL gentamicin) and transferred to culture flasks to a 37 °C incubator 
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(5-10% CO2). After growth for 10 days in vitro (DIV), cells were detach with 0.05% 
trypsin, centrifuged and plated at the density of 10,000 cells/well in poly-lysine coated 
96-well plates. Plates are grown for 14 DIV before uptake assays. 
Uptake assays. Assays were performed as described109. Briefly, using an 
Elx50® Biotek plate washer (Winooski, VT, USA), cells are washed in PBS-CM buffer. 
For dose response assays, vehicle and several concentrations of compounds 11 and 
12 (shown in figures 7-8, at 0.01 nM- 1 M) were added and incubated for 10 min at 
37oC. Uptake assays are initiated by addition of 50 nM L- [3H]-glutamate, and 
incubation is carried on for 10 min at room temperature. Non-specific uptake was 
obtained in presence of 10 M DL-TBOA. 
For kinetic assays, cells are washed in PBS-CM buffer and pre-incubated in the 
presence of either vehicle or several concentrations of the compounds, uptake 
reactions are initiated by the addition of unlabeled L-glutamate and 3H-L-glutamate 
(1–1000 M, final concentration, 99% unlabeled and 1% labeled). Incubation was 
carried on for 10 min at room temperature. Non-specific uptake was also obtained in 
presence of DL-TBOA.
Reactions were finished by washing the plates twice with PBS-CM and the 
addition of 100 μL of scintillation fluid to each well. Radioactivity was counted in a 
Microplate Scintillation and Luminescence Counter (Wallac, Shelton, CT, USA).
Examination of the effect of compounds in primary mixed neuron-glia 
cultures
In this work, we have examined the effects of both Pwx10 fraction and synthetic 
(compounds 11 and 12 in figures 7-8) in two models of excitotoxicity in primary neuron-
glia cultures. 
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Cortical cells were obtained from late embryonic stage (E17) Holtzman rats. 
These cells were plated at a density of 35,000 cells/coverslip in 12-well plates for 
immunocytochemistry assays as previously described82. 
We did not add AraC to mixed neuron-glia cultures. Culture conditions were 
optimized to contain enough glia to observe suitable expression of EAAT1 and EAAT2 
and treatment effects of compounds, while maintaining a population of neurons that is 
large enough to accurately measure neuronal survival, as previously described82. This 
was achieved by plating cells in Neurobasal media (NB) with 2% B27 supplement and 
10% Horse Serum. The media was changed 2 h after plating to NB media containing 
2% B27, 2% Horse serum, 1% glutamine, 25 μM L-glutamate and 50 μg/mL 
gentamicin. 4 days later, media was changed to NB media with 2% B27, 1% glutamine 
and 50 μg/mL gentamicin. Finally, cells received fresh NB media (with 2% B27, 1% 
glutamine and 50μg/mL gentamicin) at 8 DIV, and cultures were exposed to excitotoxic 
insults and compound treatment at 14 DIV. At 14 DIV, cultures are well-differentiated, 
markers of neuronal maturity, such as NeuN; NF-L; NF-M; GAD; TH; PSD-95 and 
synaptophysin, are well expressed137; protein content and mitochondrial respiration is 
stabilized138-139; and L-glutamate receptors are well expressed118, 140-142, as well as L-
glutamate transporters82.
These growth conditions produced approximately 15% glia in each culture82, and 
only cultures with consistent percentages of astrocytic populations across individual 
experiments and coverslips were included in the study. Any culture with a proportion 
of glia that was significantly different from a range of 7-18% (measured by One-Way 
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ANOVA followed by Newman-Keuls post hoc test for multiple comparisons performed 
on the percentage of GFAP+ in each coverslip) was excluded from the analysis.
Excitotoxic insult models
L-glutamate mediated excitotoxic insults and compound administration
At 14 DIV, cultures were examined before each experiment for cell viability 
under a TCM-BR inverted bright field microscope. Cultures that appeared unhealthy 
were discarded from further experiments. L-Glutamate and compound solutions were 
made in fresh growth media. L-glutamate (100 µM) was directly added to the mixed 
cultures for 24h. Pwx10 fraction and compound 12 (figure 8), were co-applied at 1, 10 
or 100 nM concentrations, and allowed to incubate for 24h. Additionally, as positive 
control for neuroprotection, some cultures were treated with 100 µM APV, an NMDA 
receptor blocker, which was added at the same time as the 100 µM L-glutamate insult. 
Also, to evaluate the effect of blockage of L-glutamate transport, some cultures were 
treated with the non-selective L-glutamate transporter blocker DL-TBOA (100 µM) or 
the EAAT2 specific inhibitor WAY 213613 (1 µM). These compounds were also added 
at the same time as the L-glutamate insult. 
Additionally, to test for any possible toxicity of the experimental compounds, 
cultures were treated with Pwx10 fraction or with compound 12 (figure 8) at 100 nM 
for 24 hours, without any insults. 
Oxygen-Glucose Deprivation (OGD) insults and compound 
administration
We extended our studies to evaluate the effects of Pwx10 fraction and 
compound 12 (figure 8) after OGD insults, an in vitro stroke model19, 143. Glucose-free 
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DMEM (OGD media) and regular growth media were warmed in 37C water bath. A 
hypoxic chamber (Billups-Rothenberg, San Diego, CA, USA) was sterilized in UV light 
for 20 min prior to the experiment, and pre-warmed OGD media was de-gassed for 5 
min by bubbling with a gas mixture composed of 10% H2/85% N2/5 %CO2 or 95% 
N2/5% CO2. The media on the cultures was replaced with 1 mL/well/ coverslip of de-
gassed OGD media. Plates were placed in the hypoxic chamber and were de-gassed 
for 5 min. The chamber was then sealed and put in the 37 °C incubator for 15 min, 
resulting in a 20 min insult. The choice for this insult time was based on previous 
experiments that showed that these conditions resulted in ~50% of neuronal death, 
i.e., they were appropriate to study the effect of compounds on neuronal survival 
(Figure 10). Following the OGD insult, cultures were either incubated with fresh growth 
media (vehicle control), several concentrations of Pwx10 fraction or compound 12, 
100 M APV, 100 µM TBOA, or 1 µM WAY 213613 as post-treatments. 
Immunocytochemistry assays for evaluation of neuronal survival
To evaluate neuronal health status (as a function of MAP-2) and the effect of 
treatment with compounds, cultures on 15 mm glass coverslips were fixed and 
fluorescently labelled as described144-146. As a control for initial levels of neuronal 
survival, cultures not subjected to treatments (time zero) were also examined. Briefly, 
cultures on coverslips were fixed with 2% paraformaldehyde, permeabilized with 0.1% 
Triton X-100, blocked with 5% Normal Donkey serum, washed and incubated 
overnight with primary antibodies in 5% blocking solution: anti-MAP-2 (1:1,000) and 
anti-GFAP (1:400). Then the following secondary antibodies were added: Alexa 
Fluor® 488 conjugated AffiniPure Donkey Anti-Rabbit IgG for MAP-2 detection and 
Cy™3-conjugated AffiniPure Donkey Anti-Mouse IgG for GFAP, both at 1:500, 
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prepared in blocking solution (5% normal donkey serum in PBS). After 30 min 
incubation in the dark, coverslips were washed and mounted on a slide with ProLong® 
Diamond Antifade Mountant with DAPI Thermo Fisher Scientific (Waltham, MA, USA) 
for nuclear staining. Coverslips were then sealed with clear nail polish.
Image acquisition and neuronal survival counting 
Cells were imaged with a fluorescent microscope to examine morphology and 
a confocal microscope to quantify cell survival. We used the following settings for the 
confocal microscope: quality: 1280x1024, 2.4x analog gain, and dynamic contrast. 
The exposure was set at 8 seconds and images were taken using the 30x zoom 
setting. For all experiments, 5-10 random fields/coverslip and 3-4 coverslips were 
evaluated per treatment condition. Images were taken in all 3 filters to visualize DAPI, 
Alexa-488 (for MAP-2), and Cy3 (for GFAP). For assessment of cell population, cells 
in the cultures were classified into neurons (MAP-2 positive cells) and glia (GFAP 
positive cells). The abundance of each cell type was calculated and expressed as 
percent of total, DAPI positive cells on a coverslip. 
Neuronal survival was evaluated by in a blind manner. Survival was determined 
by evaluating individual neurons for features that are indicative of neurodegeneration 
and apoptosis, such as pyknotic nuclei, membrane blebbing, and neuritis146-147. Nuclei 
that stained with DAPI but lacked significant MAP-2 staining were also classified as 
dead neurons. The percentage of neuronal survival was calculated by dividing the 
number of MAP-2 positive neurons with no morphological signs of toxicity, by the total 
number of MAP-2 positive neurons on each coverslip. 
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For each experimental condition, 5 random fields from 3-4 coverslips were 
analysed, totalling at least 100-150 neurons. Mean survival in each treatment 
condition was normalized to mean survival in the control group for each experiment. 
The normalization was performed considering the control group of each individual 
experiment as 100% of survival and obtaining the relative percentage of neuronal 
survival of each condition/treatment. Additionally, neuronal survival was evaluated 
before all insults (time zero) in at least 4 control coverslips, before beginning each 
experiment. Only sets of experiments with reasonable survival rates at time zero 
(>75%) were included in the final analysis of neuronal survival.
Images were processed using ImageJ® from the National Institute of Health 
(Bethesda, MD, USA). 
Data analysis
All data were analyzed using GraphPad Prism version 5.03 for Windows 
(GraphPad Software, La Jolla, CA, USA).
Data generated from dose-response assays on the effects of the compounds 
on L-glutamate, GABA, glycine and monoamine transport were fitted to a dose-
response curve by non-linear regression analysis using GraphPad Prism version 5.03 
for Windows. Non-specific transport (background) for L-glutamate uptake in COS-7 
cells was transfected with an empty vector (pCMV). For GABA uptakes, we obtained 
the background in the presence of specific GABA transport inhibitor nipecotic acid (1 
mM, final concentration), and for glycine uptake, in presence of sarcosine (GAT-1 
transport inhibitor, 100 M, final concentration) or N-Arachidonylglycine (specific GAT-
3 inhibitor, 100 M, final concentration). For L-glutamate uptakes in glia plated in 96 
well plates, wells received DL-TBOA (100 M final concentration) to obtain the 
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background. For monoamine transporter assays in stable transfected MDCK cells, 
naïve MDCK cells were used to obtain the background. Background values were 
subtracted from the total. EC50 and IC50 values (as the concentration of compound 
resulting in 50% of the maximum observed stimulation or inhibition, respectively), and 
efficacies are given as means ± SEM of three or four independent assays performed 
in triplicate, and normalized to percentage of control (vehicle). 
Michaelis-Menten kinetics was assumed for calculation of Km and Vmax. 
Statistical significance was assessed using One-way analysis of variance (ANOVA) 
followed by Dunnett’s or Bonferroni multiple comparisons post hoc tests with vehicle 
(for analysis of the effect of compounds) as control (* p <0.05). Background values 
were obtained either by CMV-expressing COS-7 cells or in presence of DL-TBOA (for 
glia uptakes), those values were subtracted for calculation of specific uptake values.
For neuroprotection studies, the neuronal survival was expressed as % of 
neuronal death comparing control, insult and treatments. Statistical significance was 
assessed using One-way analysis of variance (ANOVA) followed by Dunnett’s 
multiple-comparisons post hoc test with vehicle as control (* p < 0.05), or Newman-
Keuls post hoc test for multiple comparisons (# p < 0.05). 
Supporting information 
MS/MS spectra of all compounds identified from the P. bistriata venom, NMR 
and MS spectra for all compounds leading to synthesis of 4-OH-
IndAc3(Me2)4(Me2)3Arg2+, activity of constituents of the fraction Pwx2 on GABA and 
glycine transporters; lack of bioactivity of Pwx10 fraction and compounds 11 and 12 
on GABA, glycine and monoamine transporters, and L-glutamate uptake in mixed 
neuron-glia cultures in presence of specific inhibitors. 
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ALS, Amyotrophic Lateral Sclerosis; AMPA, α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid; APV, (2R)-amino-5-phosphonovaleric acid; AraC, Cytosine-
β−D-arabinofuranoside; CNS, Central Nervous System; DAPI, 4',6-Diamidino-2-
Phenylindole; DCM, dichloromethane; DIV, Days in vitro; DL-TBOA, DL- threo-β-
Benzyloxyaspartic acid; DMF, dimethylformamide; D-PBS, Dulbecco’s phosphate-
buffered saline; PBS-CM, D-PBS with 0.1 mM CaCl2 and 1 mM MgCl2 added; EAAT1-
5, Excitatory amino acid transporters 1-5, respectively; GAT-1, GABA transporter 
subtype 1, GAT-3, GABA transporter subtype 3; GlyT1, glycine transporter subtype 1; 
GlyT2, glycine transporter subtype 2; GLAST; glutamate aspartate transporter, rodent 
homologue of EAAT1, GLT-1, glutamate transporter 1, rodent homologue of EAAT2; 
EAAC1, excitatory amino acid carrier 1, rodent homologue of EAAT3; GFAP, Glial 
Fibrillary Acidic Protein; ESI-HR-MS/MS, electionspray ionization high-resolution 
tandem mass spectrometry; MAP-2, mGluR, metabotropic glutamate receptor; 
Microtubule-Associated Protein 2; NAM, negative allosteric modulation; NB media, 
Neurobasal media; NMDA, N-methyl-D-aspartate; NaOH, sodium hydroxide; OGD, 
Oxygen-glucose deprivation; PAM, positive allosteric modulation; Pwx10, 
Parawixin10; SDS, sodium dodecyl sulphate; SKF 89976A hydrochloride, 1-(4,4-
Diphenyl-3-butenyl)-3-piperidinecarboxylic acid hydrochloride; UCPH 101, 2-Amino-
5,6,7,8-tetrahydro-4-(4-methoxyphenyl)-7-(naphthalen-1-yl)-5-oxo-4H-chromene-3-
carbonitrile; UHPLC, ultra-high performance liquid chromatography; WAY 213613, N-
[4-(2-Bromo-4,5-difluorophenoxy)phenyl]-L-asparagine; WT, wild type. 
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Figure 1: Base peak chromatogram (BPC) of the P. bistriata venom with indication of 
the peaks related to previously isolated neuroprotective fractions Pwx2 and Pwx10. 
Figure 2: The MS/MS spectrum of the precursor ion m/z 175.12 [M+H]+ found in the 
crude venom of P. bistriata (top) compared to the MS/MS spectra recorded from the 
commercial reference material FrPbAII (left) and arginine (right) proving that the spider 
venom contains in fact arginine but not FrPbAII.
Figure 3: Uptake assays in COS-7 cells transfected with GABA transporters GAT-1 
and GAT-3 and glycine transporters GlyT1 and GlyT2 reveal that natural fraction Pwx2 
inhibits GABA uptake specifically through GAT-1. A. Dose-response curves of Pwx2 
fraction, B. Dose response curves of commercial FrPbAII, C. Dose-response curves 
of arginine, D. Effects of nipecotic acid (1 mM) on both GAT-1 and GAT-3 transporters 
and specific GlyT1 inhibitor sarcosine and GlyT2 inhibitor N-Arachidonyl-glycine (100 
mM) on glycine transporters. COS-7 cells transiently transfected with appropriate 
cDNA or empty vector were pre-incubated for 10 min with varied concentrations of 
compounds and reactions with 50 nM of 3H-GABA or 3H-glycine were carried out for 
10 min. Results are normalized to percentage of control (vehicle) and expressed as 
mean ± SEM of three independent experiments.
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Figure 4: Full scan (FS)-MS of the peak in the UHPLC-MS chromatogram of the P. 
bistriata crude venom (6.78 – 6.92 min), which corresponds to the doubly charged ion 
m/z 294.7 (main signal detected for the Pwx10 fraction).
Figure 5: The acylpolyamine 4-OH-IndAc3(Me2)4(Me2)3Arg2+; identified from the 
MS/MS spectrum of the precursor ion m/z 816.4 with fragment ion annotation.
Figure 6: Schematic overview for the free polyamines and acylpolyamines found in the 
venom of P. bistriata. For nomenclature and structures please see supplementary 
material.
Scheme 1: Synthesis scheme leading to 4-OH-IndAc3(Me2)4(Me2)3Arg2+; (shown as 
compound 12).
Scheme 2: Synthesis scheme of 4-OH-IndAc3(Me2)4(Me2)3Arg2+; (compound 12).
Figure 7: Fraction Pwx10 stimulates both EAAT1 and EAAT2-mediated transport. 
A. Dose response of Pwx10 fraction on L-glutamate transport mediated by EAAT1, 
EAAT2 or EAAT3 shows that the compound does not modulate EAAT3-mediated 
transport but increases EAAT1 and EAAT2; EC50s and efficacies are indicated. Cells 
were incubated with varied concentrations of compound for 10 min at 37 oC and 10 
min with 50 nM 3H-L-glutamate. Results are normalized to percentage of control 
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(vehicle) and expressed as mean ± SD of three independent experiments, B. Pwx10 
fraction augments L-glutamate uptake in a native environment of culture astrocytes. 
Cells were incubated with varied concentrations of compound for 10 min at 37 oC and 
10 min with 50 nM 3H-L-glutamate. Results are normalized to percentage of control 
(vehicle) and expressed as Mean ± SD of all the experiments, C. Effects of Pwx10 
fraction (10, 100 and 500 nM) on the kinetics of EAAT1, and D. Effects of Pwx10 
fraction (10, 100 and 500 nM) on the kinetics of EAAT2. Vmax and KM were calculated, 
and the values are presented in the table; KM was not statistically different between 
the varying concentrations of compounds analysed in this study, *** p < 0.001, Vmax 
comparing compound (100 and 500 nM) to vehicle. Assays were performed in COS-7 
cells transiently transfected with appropriate cDNA or empty vector, E. Kinetic analysis 
of L-glutamate uptake in cultured glia cells pre-incubated with vehicle, 100 nM and 
500 nM of Pwx10 fraction. Vmax and KM were calculated, and values are presented in 
the table; KM was not statistically different between treatments, ***p < 0.001, Vmax 
comparing compound to vehicle. 
Figure 8: Compounds 11 and 12 have similar activities to fraction Pwx10, modulating 
EAAT1 and EAAT2 transporter activities.
Dose responses of 12 (A) and 11 (B) on L-glutamate transport mediated by EAAT1, 
EAAT2 or EAAT3 shows that the compounds do not modulate EAAT3-mediated 
transport but increase EAAT1 and EAAT2; EC50s and efficacies are indicated. Cells 
were incubated with varied concentrations of compound for 10 min at 37 oC and 10 
min with 50 nM 3H-L-glutamate. Results are normalized to percentage of control 
(vehicle) and expressed as mean ± SD of three independent experiments, C. 12 and 
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11 augment L-glutamate uptake in a native environment of culture astrocytes. Cells 
were incubated with varied concentrations of compounds for 10 min at 37 oC and 10 
min with 50 nM 3H-L-glutamate. Results are normalized to percentage of control 
(vehicle) and expressed as Mean ± SD of all the experiments, D. Effects of 12 and 11 
(100 and 500 nM) on the kinetics of EAAT1, and E. Effects of 12 and 11 (100 and 500 
nM) on the kinetics of EAAT2. Vmax and KM were calculated, and the values are 
presented in the table; KM was not statistically different between the varying 
concentrations of compounds analysed in this study, *** p < 0.001, Vmax comparing 
compound (100 and 500 nM) to vehicle. Assays were performed in COS-7 cells 
transiently transfected with appropriate cDNA or empty vector, F. Kinetic analysis of 
L-glutamate uptake in cultured glia cells pre-incubated with vehicle, 100 nM and 500 
nM of 12 and 11. Vmax and KM were calculated, and values are presented in the table; 
KM was not statistically different between treatments, ***p < 0.001, Vmax comparing 
compound to vehicle. 
Figure 9: Neuroprotective properties of Pwx10 fraction and 4-OH-
IndAc3(Me2)4(Me2)3Arg2+ (12) in mixed neuron-glia cultures after prolonged exposure 
to L-glutamate. 
A. Representative Images of 14 DIV mixed neuron-glia cultures in control conditions, 
after treatments with 100 µM Pwx10 fraction or 100 µM L-glutamate, and after 
treatment with 100 µM L-glutamate in presence of 100 nM Pwx10 fraction, for 24 h. 
Cells were fixed and immunostained for the neuronal marker MAP-2 (green) and the 
glial marker GFAP (red), and counterstaining with the nuclear marker DAPI (blue). 
Vehicle and Pwx10 fraction treated cultures in the absence of L-glutamate do not 
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display obvious degeneration of cell death. Cell death was evident in L-glutamate 
treated cultures, as assessed by the increased number of DAPI positive, MAP-2 and 
GFAP negative cells. Co-treatment with 100 nM Pwx10 fraction reversed a portion of 
the L-glutamate toxicity by increasing MAP-2 and GFAP expression and reducing the 
number of DAPI-only cells. All images are shown at 40x magnification. Scale bar: 100 
μm.
B: Quantification of neuronal survival (normalized to control, vehicle-treated cultures). 
L-glutamate significantly reduced neuronal survival, which was mitigated by co-
treatment with Pwx10 fraction and 12 (100 nM) and the NMDA antagonist APV. Co-
treatment with Pwx10 fraction (100 nM) and the L-glutamate transporter inhibitor 
TBOA or the selective EAAT2 inhibitor WAY 23 213613 did not rescue neuronal 
damage in L-glutamate exposed cultures, suggesting that 4-OH-
IndAc3(Me2)4(Me2)3Arg2+ -mediated neuroprotection requires active L-glutamate 
transporters. 3-4 coverslips were assessed per treatment condition, and 100-150 cells 
were manually counted per treatment. Neuronal survival data is representative of 3 
independent experiments (n=9) and control levels were not statistically different for 
normalization purposes. ***p <0.001, **p <0.01, *p <0.05, vs. control (no insult), ###p 
<0.001, vs. insult, &p <0.05 Pwx10 (100 nM) + TBOA (100 mM) vs. Pwx10 fraction 
(100 nM) + WAY 213613 (1 mM).
Figure 10: Neuroprotective properties of Pwx10 fraction and 4-OH-
IndAc3(Me2)4(Me2)3Arg2+ (12) in mixed neuron-glia cultures after transient oxygen 
and glucose deprivation. 
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A. Representative Images of 14 DIV mixed neuron-glia cultures in control conditions, 
after 20 min OGD insult and after OGD insult followed by treatment with 100 µM Pwx10 
fraction, for 24 h. Cells were fixed and immunostained for the neuronal marker MAP-
2 (green) and the glial marker GFAP (red), and counterstaining with the nuclear marker 
DAPI (blue). Vehicle cultures in the absence of OGD insult do not display obvious 
degeneration of cell death. Cell death was evident after OGD insult, as assessed by 
the increased number of DAPI positive, MAP-2 and GFAP negative cells. Post-
treatment with 100 nM Pwx10 fraction or 12 reversed a portion of the L-glutamate 
toxicity by increasing MAP-2 and GFAP expression and reducing the number of DAPI-
only cells. All images are shown at 40x magnification. Scale bar: 100 μm.
B. Quantification of neuronal survival (normalized to control, vehicle-treated cultures). 
OGD insult for 20 min significantly reduced neuronal survival, which was mitigated by 
co-treatment with 10 and 100 nM Pwx10 fraction and 100 nM 12 and the NMDA 
antagonist APV. The 10 and 100 nM concentration of Pwx10 fraction showed a more 
significant neuroprotective effect than the 1 nM concentration. Post-treatment with 100 
nM Pwx10 fraction and the L-glutamate transporter inhibitor TBOA and the selective 
EAAT2 inhibitor WAY 23213613 did not rescue neuronal damage in L-glutamate 
exposed cultures, suggesting that 4-OH-IndAc3(Me2)4(Me2)3Arg2+ (12) –mediated 
neuroprotection requires active L-glutamate transporters. 3-4 coverslips were 
assessed per treatment condition, and 100-150 cells were manually counted per 
treatment. Neuronal survival data is representative of 3 independent experiments 
(n=9) and control levels were not statistically different for normalization purposes. ***p 
<0.001, *p <0.05, vs. control (no insult), ###p <0.001, vs. insult. 
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Figure 1: Base peak chromatogram (BPC) of the P. bistriata venom with indication of the peaks related to 
previously isolated neuroprotective fractions Pwx2 and Pwx10. 
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Figure 2: The MS/MS spectrum of the precursor ion m/z 175.12 [M+H]+ found in the crude venom of P. 
bistriata (top) compared to the MS/MS spectra recorded from the commercial reference material FrPbAII 
(left) and arginine (right) proving that the spider venom contains in fact arginine but not FrPbAII. 
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Figure 3: Uptake assays in COS-7 cells transfected with GABA transporters GAT-1 and GAT-3 and glycine 
transporters GlyT1 and GlyT2 reveal that natural fraction Pwx2 inhibits GABA uptake specifically through 
GAT-1. A. Dose-response curves of Pwx2 fraction, B. Dose response curves of commercial FrPbAII, C. Dose-
response curves of arginine, D. Effects of nipecotic acid (1 mM) on both GAT-1 and GAT-3 transporters and 
specific GlyT1 inhibitor sarcosine and GlyT2 inhibitor N-Arachidonyl-glycine (100 μM) on glycine 
transporters. COS-7 cells transiently transfected with appropriate cDNA or empty vector were pre-incubated 
for 10 min with varied concentrations of compounds and reactions with 50 nM of 3H-GABA or 3H-glycine 
were carried out for 10 min. Results are normalized to percentage of control (vehicle) and expressed as 
mean ± SEM of three independent experiments. 
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Figure 4: Full scan (FS)-MS of the peak in the UHPLC-MS chromatogram of the P. bistriata crude venom 
(6.78 – 6.92 min), which corresponds to the doubly charged ion m/z 294.7 (main signal detected for the 
Pwx10 fraction). 
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Figure 5: The acylpolyamine 4-OH-IndAc3(Me2)4(Me2)3Arg
2+; identified from the MS/MS spectrum of the 
precursor ion m/z 816.4 with fragment ion annotation. 
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Figure 6: Schematic overview for the free polyamines and acylpolyamines found in the venom of P. bistriata. 
For nomenclature and structures please see supplementary material. 
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Scheme 1: Synthesis scheme leading to 4-OH-IndAc3(Me2)4(Me2)3Arg
2+; (shown as compound 12). 
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Scheme 2: Synthesis scheme of 4-OH-IndAc3(Me2)4(Me2)3Arg
2+; (compound 12). 
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Figure 7: Fraction Pwx10 stimulates both EAAT1 and EAAT2-mediated transport. A. Dose response of Pwx10 
fraction on L-glutamate transport mediated by EAAT1, EAAT2 or EAAT3 shows that the compound does not 
modulate EAAT3-mediated transport, but increases EAAT1 and EAAT2; EC50s and efficacies are indicated. 
Cells were incubated with varied concentrations of compound for 10 min at 37 oC and 10 min with 50 nM 
3H-L-glutamate. Results are normalized to percentage of control (vehicle) and expressed as mean ± SD of 
three independent experiments, B. Pwx10 fraction augments L-glutamate uptake in a native environment of 
culture astrocytes. Cells were incubated with varied concentrations of compound for 10 min at 37 oC and 10 
min with 50 nM 3H-L-glutamate. Results are normalized to percentage of control (vehicle) and expressed as 
Mean ± SD of all the experiments, C. Effects of Pwx10 fraction (10, 100 and 500 nM) on the kinetics of 
EAAT1, and D. Effects of Pwx10 fraction (10, 100 and 500 nM) on the kinetics of EAAT2. Vmax and KM were 
calculated, and the values are presented in the table; KM was not statistically different between the varying 
concentrations of compounds analysed in this study, *** p < 0.001, Vmax comparing compound (100 and 
500 nM) to vehicle. Assays were performed in COS-7 cells transiently transfected with appropriate cDNA or 
empty vector, E. Kinetic analysis of L-glutamate uptake in cultured glia cells pre-incubated with vehicle, 100 
nM and 500 nM of Pwx10 fraction. Vmax and KM were calculated, and values are presented in the table; KM 
was not statistically different between treatments, ***p < 0.001, Vmax comparing compound to vehicle. 
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Figure 8: Compounds 11 and 12 have similar activities to fraction Pwx10, modulating EAAT1 and EAAT2 
transporter activities. Dose responses of 12 (A) and 11 (B) on L-glutamate transport mediated by EAAT1, 
EAAT2 or EAAT3 shows that the compounds do not modulate EAAT3-mediated transport, but increase EAAT1 
and EAAT2; EC50s and efficacies are indicated. Cells were incubated with varied concentrations of compound 
for 10 min at 37 oC and 10 min with 50 nM 3H-L-glutamate. Results are normalized to percentage of control 
(vehicle) and expressed as mean ± SD of three independent experiments, C. 12 and 11 augment L-
glutamate uptake in a native environment of culture astrocytes. Cells were incubated with varied 
concentrations of compounds for 10 min at 37 oC and 10 min with 50 nM 3H-L-glutamate. Results are 
normalized to percentage of control (vehicle) and expressed as Mean ± SD of all the experiments, D. Effects 
of 12 and 11 (100 and 500 nM) on the kinetics of EAAT1, and E. Effects of 12 and 11 (100 and 500 nM) on 
the kinetics of EAAT2. Vmax and KM were calculated, and the values are presented in the table; KM was not 
statistically different between the varying concentrations of compounds analysed in this study, *** p < 
0.001, Vmax comparing compound (100 and 500 nM) to vehicle. Assays were performed in COS-7 cells 
transiently transfected with appropriate cDNA or empty vector, F. Kinetic analysis of L-glutamate uptake in 
cultured glia cells pre-incubated with vehicle, 100 nM and 500 nM of 12 and 11. Vmax and KM were 
calculated, and values are presented in the table; KM was not statistically different between treatments, 
***p < 0.001, Vmax comparing compound to vehicle. 
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Figure 9: Neuroprotective properties of Pwx10 fraction and 4-OH-IndAc3(Me2)4(Me2)3Arg
2+ (12) in mixed 
neuron-glia cultures after prolonged exposure to L-glutamate. A. Representative Images of 14 DIV mixed 
neuron-glia cultures in control conditions, after treatments with 100 µM Pwx10 fraction or 100 µM L-
glutamate, and after treatment with 100 µM L-glutamate in presence of 100 nM Pwx10 fraction, for 24 h. 
Cells were fixed and immunostained for the neuronal marker MAP-2 (green) and the glial marker GFAP 
(red), and counterstaining with the nuclear marker DAPI (blue). Vehicle and Pwx10 fraction treated cultures 
in the absence of L-glutamate do not display obvious degeneration of cell death. Cell death was evident in L-
glutamate treated cultures, as assessed by the increased number of DAPI positive, MAP-2 and GFAP 
negative cells. Co-treatment with 100 nM Pwx10 fraction reversed a portion of the L-glutamate toxicity by 
increasing MAP-2 and GFAP expression and reducing the number of DAPI-only cells. All images are shown at 
40x magnification. Scale bar: 100 μm. B: Quantification of neuronal survival (normalized to control, vehicle-
treated cultures). L-glutamate significantly reduced neuronal survival, which was mitigated by co-treatment 
with Pwx10 fraction and 12 (100 nM) and the NMDA antagonist APV. Co-treatment with Pwx10 fraction (100 
nM) and the L-glutamate transporter inhibitor TBOA or the selective EAAT2 inhibitor WAY 23 213613 did not 
rescue neuronal damage in L-glutamate exposed cultures, suggesting that 4-OH-IndAc3(Me2)4(Me2)3Arg
2+-
mediated neuroprotection requires active L-glutamate transporters. 3-4 coverslips were assessed per 
treatment condition, and 100-150 cells were manually counted per treatment. Neuronal survival data is 
representative of 3 independent experiments (n=9) and control levels were not statistically different for 
normalization purposes. ***p <0.001, **p  <0.01, *p  <0.05, vs. control (no insult), ###p  <0.001, vs. 
insult, &p  <0.05 Pwx10 (100 nM) + TBOA (100 mM) vs. Pwx10 fraction (100 nM) + WAY 213613 (1 mM). 
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Figure 10: Neuroprotective properties of Pwx10 fraction and 4-OH-IndAc3(Me2)4(Me2)3Arg
2+; (12) in mixed 
neuron-glia cultures after transient oxygen and glucose deprivation. A. Representative Images of 14 DIV 
mixed neuron-glia cultures in control conditions, after 20 min OGD insult and after OGD insult followed by 
treatment with 100 µM Pwx10 fraction, for 24 h. Cells were fixed and immunostained for the neuronal 
marker MAP-2 (green) and the glial marker GFAP (red), and counterstaining with the nuclear marker DAPI 
(blue). Vehicle cultures in the absence of OGD insult do not display obvious degeneration of cell death. Cell 
death was evident after OGD insult, as assessed by the increased number of DAPI positive, MAP-2 and GFAP 
negative cells. Post-treatment with 100 nM Pwx10 fraction or 12 reversed a portion of the L-glutamate 
toxicity by increasing MAP-2 and GFAP expression and reducing the number of DAPI-only cells. All images 
are shown at 40x magnification. Scale bar: 100 μm. B. Quantification of neuronal survival (normalized to 
control, vehicle-treated cultures). OGD insult for 20 min significantly reduced neuronal survival, which was 
mitigated by co-treatment with 10 and 100 nM Pwx10 fraction and 100 nM 12 and the NMDA antagonist 
APV. The 10 and 100 nM concentration of Pwx10 fraction showed a more significant neuroprotective effect 
than the 1 nM concentration. Post-treatment with 100 nM Pwx10 fraction and the L-glutamate transporter 
inhibitor TBOA and the selective EAAT2 inhibitor WAY 23213613 did not rescue neuronal damage in L-
glutamate exposed cultures, suggesting that 4-OH-IndAc3(Me2)4(Me2)3Arg
2+ (12)-mediated 
neuroprotection requires active L-glutamate transporters. 3-4 coverslips were assessed per treatment 
condition, and 100-150 cells were manually counted per treatment. Neuronal survival data is representative 
of 3 independent experiments (n=9) and control levels were not statistically different for normalization 
purposes. ***p <0.001, *p <0.05, vs. control (no insult), ###p <0.001, vs. insult. 
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